Monogenic familial autoinflammatory Behçet-like syndrome/ haploinsufficiency A20 syndrome is a new form of autoinflammatory pathology. Literature review and description of cases ; Моногенный семейный аутовоспалительный Бехчето-подобный синдром/синдром гаплонедостаточности А20 — новая форма аутовоспалительной патологии. Обзор литературы и описание случаев

Συγγραφείς: Е. S. Fedorov, S. О. Salugina, Е. Yu. Zakharova, А. N. Shapovalenko, S. G. Radenska-Lopovok, V. G. Matkava, А. N. Arefieva, Е. С. Федоров, С. О. Салугина, Е. Ю. Захарова, А. Н. Шаповаленко, С. Г. Раденска-Лоповок, В. Г. Маткава, А. Н. Арефьева

Συνεισφορές: Исследование проводилось в рамках фундаментальной научной темы 1021051302580-4 РК 122040400034- 6 «Выявление клинических фенотипов и прогнозирование вариантов течения аутоиммунных и аутовоспалительных ревматических заболеваний детского возраста» в лаборатории ревматических заболеваний детского возраста ФГБНУ НИИР им. В.А. Насоновой.

Πηγή: Rheumatology Science and Practice; Vol 62, No 2 (2024); 216-226 ; Научно-практическая ревматология; Vol 62, No 2 (2024); 216-226 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: болезнь Бехчета, autoinflammatory diseases, TNFAIP3 gene, A20 haploinsufficiency, relopathies, Behçet’s disease, аутовоспалительные заболевания, ген TNFAIP3, гаплонедостаточность А20, релопатии

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3552/2369; Федоров ЕС, Салугина СО, Кузьмина НН. Развитие учения об аутовоспалительных заболеваниях в XXI в. Научно-практическая ревматология. 2018;56(Прил 4):5-18. doi:10.14412/1995-4484-2018-5-18; Vaster SJ, Kuis W, Grom A. Systemic JIA. New developments in understanding of the pathophysiology and therapy. Best Pract Clin Rheumatol. 2009;23:655-664. doi:10.1016/j.berh.2009.09.003; Efthimiou P, Nandini Moorthy L, Mavragani CP, Skokos D, Fautrel B. Adult onset Still’s disease and autoinflammation. Intern J Inflammat. 2012;Article ID 964751. doi:10.1155/2012/964751; Prieur AM, Griscelli C, Lampert F, Truckenbrodt H, Guggenheim MA, Lovell DJ, et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl. 1987;66:57-68. doi:10.3109/03009748709102523; Volpi S, Picco P, Caorsi R, Candotti F, Gattorno M. Type I interferonopathies in pediatric rheumatology. Pediatr Rheum. 2016;14:35. doi:10.1186/s12969-016-0094-4; Lo MS. Insights gained from the study of pediatric systemic lupus erythematosus. Front Immunol. 2018;9:1278. doi:10.3389/fimmu.2018.01; Лисицына ТА, Алекберова ЗС, Голоева РГ, Давыдова ГА. Болезнь Бехчета: клинические проявления, современные принципы диагностики и терапии. Научно-практическая ревматология. 2019;57(5):553-563. doi:10.14412/1995-4484-2019-553-563; Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behçet’s disease. Arch Ophthalmol. 1982;100:1445-1458.; Алекберова ЗС. Болезнь Бехчета: этнос и семейная агрегация. Научно-практическая ревматология. 2016;54(3):244-246. doi:10.14412/1995-4484-2016-244-246; Алекберова ЗС, Измаилова ФИ, Гусева ИА, Денисов ЛН, Глухова СИ, Попкова ТВ. HLA-B5/51 генотип: связь с клиническими проявлениями болезни Бехчета. Научно-практическая ревматология. 2015;53(4):367-370. doi:10.14412/1995-4484-2015-367-370; Meguro A, Mizuki N, Gul A, Kitaichi N, Ohno S Behchet’s syndrome according to classical and population genetics. In: Behchet’s Syndrome. From Pathogenesis to Treatment. Springer;2014:25-37.; Алекберова ЗС, Крылов МЮ, Гусева ИА, Насонов ЕЛ. Антиген HLA-A26(10) не ассоциирован с болезнью Бехчета в смешанной мультиэтнической выборке больных. Медицинская генетика. 2012;11(6):35-38.; Gül A, Inanç M, Ocal L, Aral O, Koniçe M. Familial aggregation of Behçet’s disease in Turkey. Ann Rheum Dis. 2000;59:622-625. doi:10.1136/ard.59.8.622; Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016;48(1):67-73. doi:10.1038/ng.3459; Aksentijevich I, Zhou Q. NF-κB pathway in autoinflammatory diseases: Dysregulation of protein modifications by ubiquitin defines a new category of autoinflammatory diseases. Front Immunol. 2017;8:399. doi:10.3389/fimmu.2017.00399; Vereecke L, Beyaert R, van Loo G. Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans. 2011;39:1086-1091. doi:10.1042/BST0391086; Aeschlimann FA, Batu ED, Canna SW, Go E, Gül A, Hoffmann P, et al. A20 haploinsufficiency (HA20): Clinical phenotypes and disease course of patients with a newly recognised NF-kBmediated autoinflammatory disease. Ann Rheum Dis. 2018;77(5):728-735. doi:10.1136/annrheumdis-2017-212403; Gans MD, Wang H, Moura NS, Aksentijevich I, Rubinstein A. A20 haploinsufficiency presenting with a combined immunodeficiency. J Clin Immunol. 2020;40:1041-1044. doi:10.1007/s10875-020-00823-5; Steiner A, Harapas CR, Masters SL, Davidson S. An update on autoinflammatory diseases: Relopathies. Curr Rheumatol Rep. 2018;20:39. doi:10.1007/s11926-018-0749-x; Rood JE, Behrens EM. Inherited Autoinflammatory syndromes. Ann Rev Pathol. 2022;17:227-249. doi:10.1146/annurev-pathmechdis-030121-041528; Zhou Q, Yu X, Demirkaya E, Deuitch N, Stone D, Tsai WL, et al. Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proc Natl Acad Sci U S A. 2016;113(36):10127-10132. doi:10.1073/pnas.1612594113; Damgaard RB, Walker JA, Marco-Casanova P, Morgan NV, Titheradge HL, Elliott PR, et al. The deubiquitinase OTULIN is an essential negative regulator of inflammation and autoimmunity. Cell. 2016;166(5):1215-1230.e20. doi:10.1016/j.cell.2016.07.019; Yildiz M, Haslak F, Adrovic A, Sahin S, Koker O, Barut K, et al. Pediatric Behçet’s disease. Front Med (Lausanne). 2021;8:627192. doi:10.3389/fmed.2021.627192; Kadowaki T, Kadowaki S, Ohnishi H A20 haploinsufficiency in East Asia. Front Immunol. 2021;12:780689. doi:10.3389/fimmu.2021.780689; Yu M-P, Xu X-S, Zhou Q, Deuitch N, Lu M-P. Haploinsufficiency of A20 (HA20): Updates on the genetics, phenotype, pathogenesis and treatment. World J Pediatr. 2020;16:575-584. doi:10.1007/s12519-019-00288-6; Потрохова ЕА, Балева ЛС, Якушева ЕН, Сафонова МП. Бехчета-подобный семейный аутовоспалительный синдром у ребенка, постоянно проживающего на территории, загрязненной радионуклидами. Российский вестник перинатологии и педиатрии. 2018;63(4):218.; Потрохова ЕА, Балева ЛС, Сипягина АЕ, Якушева ЕН, Сафонова МН. Бехчета-подобный семейный аутовоспалительный синдром. Российский вестник перинатологии и педиатрии. 2021;66(2):110-115. doi:10.21508/1027-4065-2021-66-2-110-115; Matkava V, Salugina S, Nikishina I, Shapovalenko A, Fedorov E, Kolkhidova Z. A case report of haploinsufficiency of A20 in a Russian patient with Behҫet-like disease in pediatric rheumatogist practice. Pediatric Rheumatology. 2021;19(Suppl 1):73-74. doi:10.1186/s12969-021-00632-z; Berteau F, Rouviere B, Delluc A, Nau A, Le Berre R, Sarrabay G, et al. Autosomic dominant familial Behçet disease and haploinsufficiency A20: A review of the literature. Autoimmun Rev. 2018;17(8):809-815. doi:10.1016/j.autrev.2018.02.012; Li GM, Liu HM, Guan WZ, Xu H, Wu BB, Sun L. Expanding the spectrum of A20 haploinsufficiency in two Chinese families: Cases report. BMC Med Genet. 2019;20(1):124. doi:10.1186/s12881-019-0856-1; Голоева РГ, Алекберова ЗС, Лисицына ТА, Степанова ЕА, Орлова ЛП. Поражение кишечника при болезни Бехчета. Терапевтический архив. 2019;91(5):111-119. doi:10.26442/00403660.2019.05.000247; Кузьмина НН, Федоров ЕС, Салугина СО, Алекберова ЗС. Болезнь Бехчета у детей (российский опыт). Научно-практическая ревматология. 2015;53(3):312-318. doi:10.14412/1995-4484-2015-312-318

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3552
https://doi.org/10.47360/1995-4484-2024-216-226

Hereditary periodic fevers in children ; Наследственные периодические лихорадки у детей

Συγγραφείς: S. B. Krutikhina, M. A. Kudryashova, С. Б. Крутихина, М. А. Кудряшова

Πηγή: Meditsinskiy sovet = Medical Council; № 1 (2024); 276–280 ; Медицинский Совет; № 1 (2024); 276–280 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: TRAPS, ibuprofen, auto-inflammatory diseases, family mediterranean fever, HIDS, MKD, CAPS, ибупрофен, аутовоспалительные заболевания, семейная средиземноморская лихорадка

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8106/7164; Захарова ИН, Османов ИМ, Творогова ТМ, Горяйнова АН, Дмитриева ЮА, Воробьева АС, Короид НВ. Длительная лихорадка у ребенка: в чем причина, как обследовать, лечить или не лечить? Медицинский совет. 2020;(10):151–162. https://doi.org/10.21518/2079-701X-2020-10-151-162.; Сомова ТМ. Аутовоспалительное заболевание – синдром гипериммуноглобулинемии D. Медицинский вестник Юга России. 2022;13(2):141–145. https://doi.org/10.21886/2219-8075-2022-13-2-141-145; Салугина СО, Федоров ЕС, Агафонова ЕМ. Моногенные аутовоспалительные заболевания у детей и взрослых: что необходимо знать ревматологу. Научно-практическая ревматология. 2019;57(2):125–132. https://doi.org/10.14412/1995-4484-2019-125-132.; Гатторно М. Аутовоспалительные заболевания у детей. Вопросы современной педиатрии. 2014;13(2):55–64. https://doi.org/10.14412/1995-4484-2019-125-132.; Крутихина СБ, Горелов АВ, Яблокова ЕА, Тюрина ЕН, Мелешкина АВ, Чебышева СН, Савватеева ОА. Семейная средиземноморская лихорадка у детей: современные методы диагностики и подходы к терапии болевого абдоминального синдрома. Вопросы детской диетологии. 2021;19(2):76–82. https://doi.org/10.20953/1727-5784-2021-2-76-82.; Lancieri M, Bustaffa M, Palmeri S, Prigione I, Penco F, Papa R et al. An Update on Familial Mediterranean Fever. Int J Mol Sci. 2023;24(11):9584. https://doi.org/10.3390/ijms24119584.; Diaz A, Hu C, Kastner DL, Schaner P, Reginato AM, Richards N, Gumucio DL. Lipopolysaccharide-Induced Expression of Multiple Alternatively Spliced MEFV Transcripts in Human Synovial Fibroblasts: A Prominent Splice Isoform Lacks the C-Terminal Domain That Is Highly Mutated in Familial Mediterranean Fever. Arthritis Rheum. 2004;50(11):3679–3689. https://doi.org/10.1002/art.20600.; Zadeh N, Getzug T, Grody WW. Diagnosis and Management of Familial Mediterranean Fever: Integrating Medical Genetics in a Dedicated Interdisciplinary Clinic. Genet Med. 2011;13(3):263–269. https://doi.org/10.1097/GIM.0b013e31820e27b1.; Di Donato G, d’Angelo DM, Breda L, Chiarelli F. Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives. Int J Mol Sci. 2021;22(12):6360. https://doi.org/10.3390/ijms22126360.; Zhang S. Natural history of mevalonate kinase deficiency: a literature review. Pediatr Rheumatol Online J. 2016;14(1):30. https://doi.org/10.1186/s12969-016-0091-7.; Федоров ЕС, Салугина СО, Соболева МК. Семейный случай TRAPS-синдрома в российской популяции. Современная ревматология. 2015;9(1):60–65. https://doi.org/10.14412/1996-7012-2015-1-60-65.; Shu Z, Zhang Y, Han T, Li Y, Piao Y, Sun F et al. The genetic and clinical characteristics and effects of Canakinumab on cryopyrin-associated periodic syndrome: a large pediatric cohort study from China. Front Immunol. 2023;14:1267933. https://doi.org/10.3389/fimmu.2023.1267933.; Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C et al. Treatment of autoinflammatory diseases: results from the eurofever registry and a literature review. Ann Rheum Dis. 2013;72(5):678–685. https://doi.org/10.1136/annrheumdis-2011-201268.; Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al. EULAR recommendations for the management of familial mediterranean fever. Ann Rheum Dis. 2016;75(4):644–651. https://doi.org/10.1136/annrheumdis-2015-208690.; Stahl S, Graslund T, Eriksson Karlstrom A, Frejd FY, Nygren PA, Lofblom J. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 2017;35(8):691–712. https://doi.org/10.1016/j.tibtech.2017.04.007.; Kullenberg T, Lofqvist M, Leinonen M, Goldbach-Mansky R, Olivecrona H. Long-term safety profile of anakinra in patients with severe cryopyrinassociated periodic syndromes. Rheumatology (Oxford). 2016;55(8):1499–1506. https://doi.org/10.1093/rheumatology/kew208.; Ozen S, Kuemmerle-Deschner JB, Cimaz R, Livneh A, Quartier P, Kone-Paut I et al. International retrospective chart review of treatment patterns in severe FMF, TRAPS and MKD/HIDS. Arthritis Care Res (Hoboken). 2017;69(4):578–586. https://doi.org/10.1002/acr.23120.; Nedjai B, Quillinan N, Coughlan RJ, Church L, McDermott MF, Hitman GA et al. Lessons from anti-TNF biologics: infliximab failure in a TRAPS family with the T50M mutation in TNFRSF1A. Adv Exp Med Biol. 2011;691:409–419. https://doi.org/10.1007/978-1-4419-6612-4_43.; Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041–3052. https://doi.org/10.1172/JCI98814.; Shendi HM, Devlin LA, Edgar JD. Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome. J Clin Rheumatol. 2014;20(2):103–105. https://doi.org/10.1097/01.RHU.0000442576.41537.de.; Kaplan E, Mukamel M, Barash J, Brik R, Padeh S, Berkun Y et al. Protracted febrile myalgia in children and young adults with familial mediterranean fever: analysis of 15 patients and suggested criteria for working diagnosis. Clin Exp Rheumatol. 2007;25(4):114–117. Available at: https://pubmed.ncbi.nlm.nih.gov/17949564.; Морозова ТЕ, Андрущишина ТБ, Антипова ЕК. Ибупрофен: безопасность и эффективность применения в широкой клинической практике. Терапевтический архив. 2013;85(3):118–124. Режим доступа: https://www.mediasphera.ru/issues/terapevticheskij-arkhiv/2013/3/030040-36602013322.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/8106
https://doi.org/10.21518/ms2024-024

PFAPA-синдром (синдром Маршалла) у ребенка 1,6 лет: да или нет? ; PFAPA-syndrome (Marshall syndrome) in a 1.6-year-old child: yes or no?

Συγγραφείς: Korchagina, A. P., Lepeshkova, T. S., Корчагина, А. П., Лепешкова, Т. С.

Πηγή: Сборник статей

Θεματικοί όροι: MARSHALL SYNDROME, PFAPA SYNDROME, AUTO-INFLAMMATORY DISEASES, PERIODIC FEVER, PHARYNGITIS, СИНДРОМ МАРШАЛЛА, PFAPA-СИНДРОМ, АУТОВОСПАЛИТЕЛЬНЫЕ ЗАБОЛЕВАНИЯ, ПЕРИОДИЧЕСКАЯ ЛИХОРАДКА, ФАРИНГИТ

Περιγραφή αρχείου: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: материалы VII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 17-18 мая 2022 г.; http://elib.usma.ru/handle/usma/10010

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/10010

Autoinflammatory disease syndrome of hyperimmunoglobulinemia D ; Аутовоспалительное заболевание синдром гипериммуноглобулинемии D

Συγγραφείς: T. M. Somova, Т. М. Сомова

Πηγή: Medical Herald of the South of Russia; Том 13, № 2 (2022); 141-145 ; Медицинский вестник Юга России; Том 13, № 2 (2022); 141-145 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2022-13-2

Θεματικοί όροι: аутовоспалительные заболевания, children, autoinflammatory diseases, дети

Περιγραφή αρχείου: application/pdf

Relation: https://www.medicalherald.ru/jour/article/view/1529/894; Hansmann S, Lainka E, Horneff G, Holzinger D, Rieber N, et al. Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative. Pediatr Rheumatol Online J. 2020;18(1):17. DOI:10.1186/s12969-020-0409-3.; Krainer j, Siebenhandl S, weinhäusel A. Systemic autoinflammatory diseases. J Autoimmun. 2020;109:102421. DOI:10.1016/j.jaut.2020.102421.; Барабанова О.В., Коноплeва Е.А., Продеус А.П., щербина А.Ю. Периодические синдромы. Трудный пациент. 2007;5(2): 21-24. eLIBRARY ID: 16861557; Салугина С.О., Каменец Е.А., Федоров Е.С., Захарова Е.Ю., Каледа М.И. Результаты молекулярно-генетического скрининга мутаций генов NLRP3, TNFRSF1A, MVK у пациентов с аутовоспалительными заболеваниями и системным ювенильным артритом. Современная ревматология. 2017;11(3):33-43. DOI:10.14412/1996-7012-2017-3-33-43; Barron K., Athreya B., Kastner D. Periodic fever syndromes and other inherited autoinflammatory diseases in: Cassidy jT, editor. Textbook of pediatric rheumatology. 7th ed. Elsevier Saunders; 2015.; Гатторно М. Аутовоспалительные заболевания у детей. Вопросы современной педиатрии. 2014;13(2):55-64. eLIBRARY ID: 21467355; Di Donato G, d'Angelo DM, Breda L, Chiarelli F. Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives. Int J Mol Sci. 2021;22(12):6360. DOI:10.3390/ijms22126360.; Дубко М.Ф., Раупов Р.К., Канева М.А., Суспицын Е.Н., Костик М.М. Синдром дефицита мевалонаткиназы у ребенка раннего возраста: ключевые аспекты диагностики и лечения. Педиатрия. Журнал им. Г.Н. Сперанского. 2021;100(2):276-283. DOI:10.24110/0031-403x-2021-100-2-276-283; Румянцев А.Г., Демина О.М. Аутовоспалительные заболевания: современная концепция патогенеза, клиники и диагностики. Педиатрия. Журнал им. Г.Н. Сперанского. 2020;99(3):211-219. DOI:10.24110/0031-403x-2020-99-3-211-219; Favier LA, Schulert GS. Mevalonate kinase deficiency: current perspectives. Appl Clin Genet. 2016;9:101-10. DOI:10.2147/TACG.S93933.; Munoz MA, jurczyluk j, Simon A, Hissaria P, Arts Rjw, et al. Defective Protein Prenylation in a Spectrum of Patients with Mevalonate Kinase Deficiency. Front Immunol. 2019;10:1900. DOI:10.3389/fimmu.2019.01900.; Rodrigues F, Philit jB, Giurgea I, Anglicheau D, Roux jj, et al. AA amyloidosis revealing mevalonate kinase deficiency: A report of 20 cases including two new French cases and a comprehensive review of literature. Semin Arthritis Rheum. 2020;50(6):1370- 1373. DOI:10.1016/j.semarthrit.2020.03.005.; Ozen S, Kuemmerle-DeschnerjB, Cimaz R, Livneh A, Quartier P, et al. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care Res (Hoboken). 2017;69(4):578- 586. DOI:10.1002/acr.23120.; Козлова А.Л., Варламова Т.В., Зимин С.Б., Новичкова Г.А., щербина А.Ю. Опыт ведения больных с гипep-IGD-синдромом (синдромом дефицита мевалонаткиназы). Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2016;15(1):46–53. DOI:10.20953/1726-1708-2016-1-46-53; Патрушева Ю.С., Бакрадзе М.Д. Синдром периодической лихорадки с дефицитом мевалонаткиназы (синдром гипериммуноглобулинемии D) у детей. Вопросы современной педиатрии. 2012;11(2):140-145. eLIBRARY ID: 17705237; Gattorno M, Sormani MP, D'Osualdo A, Pelagatti MA, Caroli F, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum. 2008;58(6):1823-32. DOI:10.1002/art.23474.; https://www.medicalherald.ru/jour/article/view/1529

Διαθεσιμότητα: https://www.medicalherald.ru/jour/article/view/1529
https://doi.org/10.21886/2219-8075-2022-13-2-141-145

The Clinical Course and Outcomes of Familial Mediterranean Fever in Crimean Tatar Patients: Preliminary Results of Case Series ; Течение и исходы семейной средиземноморской лихорадки у пациентов крымско-татарской национальности: предварительные результаты исследования серии случаев

Συγγραφείς: Olga V. Zhogova, Sergey V. Ivanovskiy, Natalya V. Lagunova, Anastasia V. Tumakova, Mikhail M. Kostik, О. В. Жогова, С. В. Ивановский, Н. В. Лагунова, А. В. Тумакова, М. М. Костик

Συνεισφορές: The article has been funded by Novartis. Company employees did not participate in planning, conducting and discussing of the results of this study., Статья опубликована при поддержке компании «Новартис». Сотрудники компании не участвовали в планировании, проведении и обсуждении результатов настоящего исследования.

Πηγή: Current Pediatrics; Том 19, № 3 (2020); 200-206 ; Вопросы современной педиатрии; Том 19, № 3 (2020); 200-206 ; 1682-5535 ; 1682-5527

Θεματικοί όροι: аутовоспалительные заболевания, familial Mediterranean fever, Crimean Tatar, periodic fever, autoinflammatory diseases, семейная средиземноморская лихорадка, крымские татары, периодическая лихорадка

Περιγραφή αρχείου: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document

Relation: https://vsp.spr-journal.ru/jour/article/view/2396/941; https://vsp.spr-journal.ru/jour/article/view/2396/1000; Aksentijevich I, Kastner DL. Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol. 2011;7(8):469–478. doi:10.1038/nrrheum.2011.94.; Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006;103(26):9982–9987. doi:10.1073/pnas.0602081103.; Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43(2):227–253. doi:10.1016/0002-9343(67)90167-2.; Yilmaz E, Ozen S, Balci B, et al. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet. 2001;9(7):553–555. doi:10.1038/sj.ejhg.5200674.; Touitou I. Standardized testing for mutations in familial Mediterranean fever. Clin Chem. 2003;49(11):1781–1782. doi:10.1373/clinchem.2003.025791.; Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet. 2001;9(7):473–483. doi:10.1038/sj.ejhg.5200658.; The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90(4):797–807. doi:10.1016/s0092-8674(00)80539-5.; French FMFC. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17(1):25–31. doi:10.1038/ng0997-25.; Padeh S, Shinar Y, Pras E, et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever. J Rheumatol. 2003;30(1):185–190.; Marek-Yagel D, Berkun Y, Padeh S, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009;60(6):1862–1866. doi:10.1002/art.24570.; Booty MG, Chae JJ, Masters SL, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum. 2009;60(6):1851–1861. doi:10.1002/art.24569.; Ece A, Cakmak E, Uluca U, et al. The MEFV mutations and their clinical correlations in children with familial Mediterranean fever in southeast Turkey. Rheumatol Int. 2014;34(2):207–212. doi:10.1007/s00296-013-2858-1.; Kastner DL, Aksentijevich I. Intermittent and periodic arthritis syndromes. In: Koopman WJ, Moreland LW, eds. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Philadelphia, USA: Lippincott Williams and Wilkins; 2005. pp. 1411–1461.; Жогова О.В., Лагунова Н.В., Ивановский С.В. и др. Семейная средиземноморская лихорадка в Республике Крым: описание серии случаев с анализом исторических и этнографических аспектов заболевания. Научно-практическая ревматология. — 2019. — Т. 57, № 3. — С. 339–344.; Tsuchiya-Suzuki A, Yazaki M, Nakamura A, et al. Clinical and genetic features of familial Mediterranean fever in Japan. J Rheumatol. 2009;36(8):1671–1676. doi:10.3899/jrheum.081278.; Lim AL, Jang HJ, Han JW, et al. Familial Mediterranean fever: the first adult case in Korea. J Korean Med Sci. 2012;27(11): 1424–1427. doi:10.3346/jkms.2012.27.11.1424.; Li J, Zhang Y, Wang W, et al. Three cases with familial Mediterranean fever misdiagnosed as juvenile idiopathic arthritis. Zhonghua Er Ke Za Zhi. 2017;55(5):383–387. doi:10.3760/cma.j.issn.0578-1310.2017.05.015.; Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019;78(8): 1025–1032. doi:10.1136/annrheumdis-2019-215048.; Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–651. doi:10.1136/annrheumdis-2015-208690.; Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40(10): 1879–1885. doi:10.1002/art.1780401023.; Pras M. Familial Mediterranean fever: from the clinical syndrome to the cloning of the pyrin gene. Scand J Rheumatol. 1998;27(2): 92–97. doi:10.1080/030097498440949.; Yalcinkaya F, Cakar N, Misirlioglu M, et al. Genotypephenotype correlation in a large group of Turkish patients with familial mediterranean fever: evidence for mutation-independent amyloidosis. Rheumatology (Oxford). 2000;39(1):67–72. doi:10.1093/rheumatology/39.1.67.; Ozen S, Demirkaya E, Amaryan G, et al. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis. 2014;73(4):662–667. doi:10.1136/annrheumdis-2012-202708.; Ozen S, Aktay N, Lainka E, et al. Disease severity in children and adolescents with familial Mediterranean fever: a comparative study to explore environmental effects on a monogenic disease. J Clin Rheumatol. 2013 Aug;19(5):246-51. doi:10.1097/RHU.0b013e31829ce005.; Berkun Y, Ben-Chetrit E, Klar A, Ben-Chetrit E. Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever are they more frequent? Semin Arthritis Rheum. 2007;36(5): 316–321. doi:10.1016/j.semarthrit.2006.11.002.; Barut K, Sahin S, Adrovic A, et al. Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int. 2018;38(1):67–74. doi:10.1007/s00296-017-3796-0.; Rawashdeh MO, Majeed HA. Familial Mediterranean fever in Arab children: the high prevalence and gene frequency. Eur J Pediatr. 1996;155(7):540–544. doi:10.1007/bf01957901.; Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84(1):1–11. doi:10.1097/01.md.0000152370.84628.0c.; Mukhin NA, Kozlovskaya LV, Bogdanova MV, et al. Predictors of AA amyloidosis in familial Mediterranean fever. Rheumatol Int. 2015;35(7):1257–1261. doi:10.1007/s00296-014-3205-x.; Eshed I, Rosman Y, Livneh A, et al. Exertional leg pain in familial Mediterranean fever: a manifestation of an underlying enthesopathy and a marker of more severe disease. Arthritis Rheumatol. 2014;66(11):3221–3226. doi:10.1002/art.38797.; Jarjour RA, Al-Berrawi S. Familial Mediterranean fever in Syrian children: phenotype-genotype correlation. Rheumatol Int. 2015; 35(4):629–634. doi:10.1007/s00296-014-3116-x.; Manna R, Cerquaglia C, Curigliano V, et al. Clinical features of familial Mediterranean fever: an Italian overview. Eur Rev Med Pharmacol Sci. 2009;13 Suppl 1:51–53.; Colak S, Tekgoz E, Cinar M, Yilmaz S. The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: A retrospective study of 15 patients. Mod Rheumatol. 2020:1–3. doi:10.1080/14397595.2019.1709258.; Ugurlu S, Hacioglu A, Adibnia Y, et al. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. Orphanet J Rare Dis. 2017;12(1):105. doi:10.1186/s13023-017-0642-0.; Akar S, Cetin P, Kalyoncu U, et al. Nationwide experience with off-label use of interleukin-1 targeting treatment in Familial Mediterranean Fever patients. Arthritis Care Res (Hoboken). 2018; 70(7):1090–1094. doi:10.1002/acr.23446.; Gul A. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. Best Pract Res Clin Rheumatol. 2016 Apr;30(2):296-303. doi:10.1016/j.berh.2016.09.001.; De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018;378(20):1908–1919. doi:10.1056/NEJMoa1706314.; Laskari K, Boura P, Dalekos GN. Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever. J Rheumatol. 2017;44(1):102–109. doi:10.3899/jrheum.160518.

Διαθεσιμότητα: https://vsp.spr-journal.ru/jour/article/view/2396
https://doi.org/10.15690/vsp.v19i3.2115

PROSPECTS FOR USING COLCHICINE IN MEDICINE: NEW EVIDENCE ; Перспективы применения колхицина в медицине: новые данные

Συγγραφείς: Z. S. Alekberova, E. L. Nasonov, З. С. Алекберова, Е. Л. Насонов

Πηγή: Rheumatology Science and Practice; Vol 58, No 2 (2020); 183-190 ; Научно-практическая ревматология; Vol 58, No 2 (2020); 183-190 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: атеросклероз, autoinflammatory diseases, gout, Familial Mediterranean Fever, Behсet's disease, atherosclerosis, аутовоспалительные заболевания, подагра, семейная средиземноморская лихорадка, болезнь Бехчета

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2876/1952; Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251-60. doi:10.1136/pgmj.2006.052688; Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716-24. doi:10.1038/ni.3731; Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol. 2017;18(8):832-42. doi:10.1038/ni.3777; McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3:1242-8. doi:10.1371/journal.pmed.0030297; Kahlenberg JM, Kang I. Clinicopathologic significance of inflammasome activation in autoimmune diseases. Arthritis Rheum. 2019 Sep 28. doi:10.1002/art.41127; Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi:10.1136/annrheumdis-2017-211555; Насонов ЕЛ. Новые направления фармакотерапии иммуновоспалительных ревматических заболеваний. Терапевтический архив. 2019;91(8):98-107. doi:10.26442/00403660.2019.08.000406 [Nasonov EL. New directions of pharmacotherapy of immuneinflammatory rheumatic diseases. Therapeutic Archive. 2019;91(8):98-107. doi:10.26442/00403660.2019.08.000406 (In Russ.)].; Hernandez-Santana YE, Giannoudaki E, Leon G, et al. Current perspectives on the interleukin-1 family as targets for inflammatory disease. Eur J Immunol. 2019;49(9):1306-20. doi:10.1002/eji.201848056; Roubille F, Kritikou E, Busseuil D, et al. Colchicine: an old wine in a new bottle? Antiinflam Antiallerg Agents Med Chem. 2013;12:14-23. doi:10.2174/1871523011312010004; Leung YY, Yao Hui LL, Kraus VB. Colchicine – update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341-50. doi:10.1016/j.semarthrit.2015.06.013; Angelidis C, Kotsialou Z, Kossyvakis C, et al. Colchicine pharmacokinetics and mechanism of action. Curr Pharm Des. 2018;24(6):659-63. doi:10.2174/138161282466618012; Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16:407-20. doi:10.1038/nri.2016.58; Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633-52. doi:10.1038/nrd3800; Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612-32. doi:10.1038/s41584-019-0277-8; Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77. doi:10.14412/1995-4484-2016-60-77; Stack J, Ryan J, McCarthy G. Colchicine: New Insight to an old drug. Am J Ther. 2015;22(5):e151-157. doi:10.1097/01.mjt.0000433937.07244.e1; Dalbeth N, Choi HK, Joosten LAB, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69. doi:10.1038/s41572-019-0115-y 18. Martinon F. Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev. 2010;233(1):218-32. doi:10.1111/j.0105-2896.2009.00860.x; Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. Clin Ther. 2014;36(10):1465-79. doi:10.1016/j.clinthera.2014.07.017; Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987;17:301-4. doi:10.1111/j.1445-5994.1987.tb01232.x; Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-8. doi:10.1002/art.27327; Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64:1447-61. doi:10.1002/acr.21773; Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29-42. doi:10.1136/annrheumdis-2016-209707; Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. 456 с.; Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429-32.; Paulus HE, Schlosstein LH, Godfrey RG, et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 1974;17:609-14. doi:10.1002/art.1780170517; Karimzadeh H, Nazari J, Mottaghi P, Kabiri P. Different duration of Colchicine for preventing recurrence of gouty arthritis. J Res Med Sci. 2006;11:104-7.; Roddy E, Mallen CD; CONTACT trial authors. Naproxen or low-dose colchicine for gout flares in primary care? Response to: 'Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care' by Parperis et al. Ann Rheum Dis. 2019 Dec 4. doi:10.1136/annrheumdis-2019-216671; Wortmann RL, MacDonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32:2386-97. doi:10.1016/j.clinthera.2011.01.008; Елисеев МС. Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям. Научно-практическая ревматология. 2017;55(6):600-9. doi:10.14412/1995-4484-2017-600-609; McCarthy GM, Dunne A. Calcium crystal deposition diseases – beyond gout. Nat Rev Rheumatol. 2018;14(10):592-602. doi:10.1038/s41584-018-0078-5; Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011;70:571-5. doi:10.1136/ard.2010.139360; Владимиров СА, Елисеев МС. Современная стратегия лечения болезни депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2018;56(6):746-52. doi:10.14412/1995-4484-2018-746-752; Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheum. 2020;72(2):220-33. doi:10.1002/art.41142; Migliore A, Gigliucci G, Alekseeva L, et al. Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. Ther Adv Musculoskelet Dis. 2019 Dec 19;11:1759720X19893800. doi:10.1177/1759720X19893800; Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-89. doi:10.1016/j.joca.2019.06.011; Conway R, McCarthy GM. Calcium-containing crystals and osteoarthritis: an unhealthy alliance. Curr Rheumatol Rep. 2018;20(3):13. doi:10.1007/s11926-018-0721-9; Frallonardo P, Ramonda R, Peruzzo L, et al. Basic calcium phosphate and pyrophosphate crystals in early and late osteoarthritis: relationship with clinical indices and inflammation. Clin Rheumatol. 2018;37(10):2847-53. doi:10.1007/s10067-018-4166-3; McAllister MJ, Chemaly M, Eakin AJ, et al. NLRP3 as a potentially novel biomarker for the management of osteoarthritis. Osteoarthritis Cartilage. 2018;26(5):612-9. doi:10.1016/j.joca.2018.02.901; Ghouri A, Conaghan PG. Treating osteoarthritis pain: recent approaches using pharmacological therapies. Clin Exp Rheumatol. 2019;37 Suppl 120(5):124-9.; Vincent TL. IL-1 in osteoarthritis: time for a critical review of the literature. F1000Res. 2019 Jun 21;8. doi:10.12688/f1000research.18831.1; Mobasheri A, van Spil WE, Budd E, et al. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes. Curr Opin Rheumatol. 2019;31(1):80-9. doi:10.1097/BOR.0000000000000567; Еzen S, Batu ED, Demir S. Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management. Front Immunol. 2017;8:253. doi:10.3389/fimmu.2017.00253; Grattagliano I, Bonfrate L, Ruggiero V, et al. Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther. 2014;95(1):89-97. doi:10.1038/clpt.2013.148; El Hasbani G, Jawad A, Uthman I. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF). Orphanet J Rare Dis. 2019;14(1):224. doi:10.1186/s13023-019-1201-7; Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75:644-51. doi:10.1136/annrheumdis-2015-208690; Ozaltin F, Bilginer Y, Gü lhan B, et al. Diagnostic validity of colchicine in patients with Familial Mediterranean fever. Clin Rheumatol. 2014;33(7):969-74. doi:10.1007/s10067-014-2598-y; Ali NS, Sartori-Valinotti JC, Bruce AJ. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome. Clin Dermatol. 2016;34(4):482-6. doi:10.1016/j.clindermatol.2016.02.021; Manthiram K, Lapidus S, Edwards KC. Unraveling the pathogenesis of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis through genetic, immunologic, and microbiologic discoveries: an update. Curr Opin Rheumatol. 2017;29(5):493-9. doi:10.1097/BOR.0000000000000418; Adrovic A, Sahin S, Barut K, Kasapcopur O. Familial Mediterranean fever and periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome: shared features and main differences. Rheumatol Int. 2019;39(1):29-36. doi:10.1007/s00296-018-4105-2; Butbul Aviel Y, Tatour S, Gershoni Baruch R, Brik R. Colchicine as a therapeutic option in periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome. Semin Arthritis Rheum. 2016;45(4):471-4. doi:10.1016/j.semarthrit.2015.07.005; Dusser P, Hengten V, Neven B, Kone-Paut I. Is colchicine an effective treatment in Periodic Fever, Aphthous stomatitis, Pharyngitis and Cervical adenitis (PFAPA) syndrome? Joint Bone Spine. 2016;83(4):406-11. doi:10.1016/j.jbspin.2015.08.017; Gaggiano C, Rigante D, Sota J, et al. Treatment options for periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome in children and adults: a narrative review. Clin Rheumatol. 2019;38(1):11-7. doi:10.1007/s10067-018-4361-2; Yazici H, Seyahi E, Hatemi G, Yazici Y. Behcet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107-19. doi:10.1038/nrrheum.2018.3; Алекберова ЗС. Болезнь Великого шелкового пути: от преданий в XXI век. Научно-практическая ревматология. 2015;53(1):5-8. doi:10.14412/1995-4484-2015-1-4; Алекберова ЗС. Болезнь Бехчета (лекция). Научно-практическая ревматология. 2013;51(1):52-8. doi:10.14412/1995-4484-2013-1202; Gul A. Pathogenesis of Behcet's disease: autoinflammatory features and beyond. Semin Immunopathol. 2015;37(4):413-8. doi:10.1007/s00281-015-0502-8. Epub 2015 Jun 12.; Leccese P, Ozguler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Behcet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behcet's syndrome. Semin Arthritis Rheum. 2019;48(4):752-62. doi:10.1016/j.semarthrit.2018.05.008; Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis. 2018 ;77(6):808-18. doi:10.1136/annrheumdis-2018-213225; Лисицына ТА, Алекберова ЗС, Голоева РГ. Новые рекомендации по ведению пациентов с болезнью/синдромом Бехчета (EULAR, 2018). Научно-практическая ревматология. 2019;57(2):133-41. doi:10.14412/1995-4484-2019-133-141; Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet's disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191-7. doi:10.1007/s10067-016-3506-4; Fontes V, Machet L, Huttenberger B, et al. Recurrent aphthous stomatitis: treatment with colchicine. An open trial of 54 cases. Ann Dermatol Venereol. 2002;129:1365-9.; Pakfetrat A, Mansourian A, Momen-Heravi F, et al. Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: A double-blind randomized clinical trial. Clin Invest Med. 2010;33:E189-95. doi:10.25011/cim.v33i3.13725; Robinson KP, Chan JJ. Colchicine in dermatology: A review. J Dermatol. 2018;59(4):278-85. doi:10.1111/ajd.12795; Dasgeb B, Kornreich D, McGuinn K, et al. Colchicine: an ancient drug with novel applications. Br J Dermatol. 2018;178(2):350-6. doi:10.1111/bjd.15896; Kuemmerle-Descner JB, Schock AL, Nansmann S, Benseler SM. Colchicine: an effective treatment option for unclassified autoinflammatory disease in children. Ann Rheum Dis. 2018. doi:10.1136/annrheumdis-2018-eular.7473; Deftereos S, Giannopoulos G, Papoutsidakis N, et al. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol. 2013;62(20):1817-25. doi:10.1016/j.jacc.2013.08.726; Martinez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018 Feb;269:262-71. doi:10.1016/j.atherosclerosis.2017.12.027; Nidorf SM, Thompson PL. Why colchicine should be considered for secondary prevention of atherosclerosis: an overview. Clin Ther. 2019;41(1):41-8. doi:10.1016/j.clinthera.2018.11.016; Adler Y, Charron P, Imazio M, et al. European Society of C 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for CardioThoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-64. doi:10.1093/eurheartj/ehv318; Cantarini L, Lopalco G, Selmi C, et al. Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmun Rev. 2015;14(2):90-7. doi:10.1016/j.autrev.2014.10.005; Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232-7. doi:10.1016/S0140-6736(13)62709-9; Imazio M, Brucato A, Ferrazzi P, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312(10):1016-23. doi:10.1001/jama.2014.11026; Izadi Amoli A, Bozorgi A, HajHossein Talasaz A, et al. Efficacy of colchicine versus placebo for the treatment of pericardial effusion after open-heart surgery: a randomized, placebo-controlled trial. Am Heart J. 2015;170(6):1195-201. doi:10.1016/j.ahj.2015.09.020; Finkelstein Y, Shemesh J, Mahlab K, et al. Colchicine for the prevention of postpericardiotomy syndrome. Herz. 2002;27(8):791-4. doi:10.1007/s00059-002-2376-5; Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165(17):1987-91. doi:10.1001/archinte.165.17.1987; Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112(13):2012-6. doi:10.1161/CIRCULATIONAHA.105.542738; Imazio M, Trinchero R, Brucato A, et al. COlchicine for the prevention of the post- pericardiotomy syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010;31(22):2749-54. doi:10.1093/eurheartj/ehq319; Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409-14. doi:10.7326/0003-4819-155-7-201110040-00359; Imazio M, Brucato A, Cemin R, et al. Investigators I. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-8. doi:10.1056/NEJMoa1208536; Lutschinger LL, Rigopoulos AG, Schlattmann P, et al. Metaanalysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome. BMC Cardiovasc Disord. 2019;19(1):207. doi:10.1186/s12872-019-1190-4; Imazio M, Adler Y. Management of pericardial effusion. Eur Heart J. 2013;34:1186-97. doi:10.1093/eurheartj/ehs372; Feng D, Glockner J, Kim K, et al. Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory markers can predict the reversibility of constrictive pericarditis after antiinflammatory medical therapy: a pilot study. Circulation 2011;124:1830-7. doi:10.1161/CIRCULATIONAHA.111.026070; Syed FF, Schaff HV, Oh JK. Constrictive pericarditis – a curable diastolic heart failure. Nat Rev Cardiol. 2014;11:530-44. doi:10.1038/nrcardio.2014.100; Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nat Rev Immunol. 2019;19:63-6. doi:10.1038/s41577-018-0098-z; Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol. 2018;18:733-44. doi:10.1038/s41577-018-0065-8; Deftereos SG, Vrachatis DA, Angelidis C, et al. The role of colchicine in treating postoperative and post-catheter ablation atrial fibrillation. Clin Ther. 2019;41(1):21-9. doi:10.1016/j.clinthera.2018.08.008; Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-38. doi:10.1016/j.jacc.2009.09.009; Насонов ЕЛ. Попкова ТВ. Атеросклероз: перспективы противовоспалительной терапии. Терапевтический архив. 2018;90(5):4-12.; Libby PJ. A interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Amer Coll Cardiol. 2017;70(18):2278-89. doi:10.1016/j.jacc.2017.09.028; Fiolet ATL, Nidorf SM, Mosterd A, Cornel JH. Colchicine in stable coronary artery disease. Clin Ther. 2019;41(1):30-40. doi:10.1016/j.clinthera.2018.09.011; Vaidya K, Martinez G, Patel S. The role of colchicine in acute coronary syndromes. Clin Ther. 2019;41(1):11-20. doi:10.1016/j.clinthera.2018.07.023; Hemkens LG, Ewald H, Gloy VL, et al. Colchicine for prevention of cardiovascular events. In: Hemkens LG, ed. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2016.; Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Lowdose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404-10. doi:10.1016/j.jacc.2012.10.027; Vaidya K, Arnott C, Martinez GJ, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT Coronary Angiography Study. JACC Cardiovascular Imaging 2017 Oct 14. doi:10.1016/j.jcmg.2017.08.013; Deftereos S, Giannopoulos G, Angelidis C, et al. AntiInflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015;132:1395-403. doi:10.1161/CIRCULATIONAHA.115.017611; Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of lowdose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-505. doi:10.1056/NEJMoa1912388; Ridker PM, Everett BM, Thuren T, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31. doi:10.1056/NEJMoa1707914; Hennessy T, Soh L, Bowman M, et al. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J. 2019;215:62-9. doi:10.1016/j.ahj.2019.06.003; Nidorf SM, Fiolet ATL, Eikelboom JW, et al; LoDoCo2 Investigators. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J. 2019;218:46-56. doi:10.1016/j.ahj.2019.09.011; Nguyen MT, Fernando S, Schwarz N, et al. Inflammation as a therapeutic target in atherosclerosis. J Clin Med. 2019;8(8). doi:10.3390/jcm8081109; De Vera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010;69(6):1162-4. doi:10.1136/ard.2009.122770; Seminog OO, Goldacre MJ. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford). 2013;52(12):2251-9. doi:10.1093/rheumatology/ket293; Kuo CF, Yu KH, See LC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford). 2013;52(1):111-7. doi:10.1093/rheumatology/kes169; Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39:1458-64. doi:10.3899/jrheum.111533; Solomon DH, Liu C-C, Kuo I-H, et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75:1674-9. doi:10.1136/annrheumdis-2015-207984; Solomon DH, Glynn RJ, MacFadyen JG, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535-42. doi:10.7326/M18-1167; Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48(5):407-14. doi:10.3109/15563650.2010.495348; Ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74(9):1636-44. doi:10.1136/annrheumdis-2015-207546 110. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477-89. doi:10.1038/s41577-019-0165-0

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2876
https://doi.org/10.14412/1995-4484-2020-183-190

Challenging diagnosis: coexistence of two rare diseases - familial mediterranean fever and loyez-dietz syndrome type 3 ; Диагностические трудности: сосуществование двух редких заболеваний - семейной средиземноморской лихорадки и синдрома Лойса-Дитца 3 типа ; Difficulté de diagnostic: cohérence de deux maladies rares – fièvre méditerranée familiale et la syndrome Loeys-Dietz type 3

Συγγραφείς: REVENCO, Ninel, ANDRIES, Lucia, SACARA, Victoria, DORIF, Alexandr, BARBA, Doina, EREMCIUC, Rodica, GAIDARJI, Olga

Πηγή: One Health & Risk Management ; Vol. 1 No. 2 (2020); 68-72 ; Vol 1 Nr 2 (2020); 68-72 ; Том 1 № 2 (2020); 68-72 ; 2587-3466 ; 2587-3458

Θεματικοί όροι: autoinflammatory diseases, familial Mediterranean fever, children, maladies auto-inflammatoires, fièvre méditerranée familiale, enfants, аутовоспалительные заболевания, семейная средиземноморская лихорадка, дети

Περιγραφή αρχείου: application/pdf

Relation: https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/74/39

Διαθεσιμότητα: https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/74
https://doi.org/10.38045/ohrm.2020.1.18

SYSTEMATIC JUVENILE ARTHRITIS: A MODERN VIEW ON PATHOGENESIS, DIAGNOSIS AND TREATMENT

Συγγραφείς: Людмила Николаевна Игишева, Светлана Сергеевна Притчина

Πηγή: Мать и дитя в Кузбассе, Vol 17, Iss 3, Pp 4-9 (2016)

Θεματικοί όροι: аутовоспалительные заболевания, системный вариант ювенильного артрита, синдром висслера-фанкони, лихорадка, Pediatrics, RJ1-570, Gynecology and obstetrics, RG1-991

Περιγραφή αρχείου: electronic resource

Relation: http://mednauki.ru/index.php/MD/article/view/45; https://doaj.org/toc/1991-010X; https://doaj.org/toc/2542-0968

Σύνδεσμος πρόσβασης: https://doaj.org/article/d0a32f6ca3394b0dbc5b39c9941b19af

The PFAPA syndrome: current paradigm and a clinical case description ; PFAPA-синдром: современная парадигма и описание клинического случая

Συγγραφείς: Kuznetsova M.A., Zryachkin N.I., Tsareva Y.A., Elizarova T.V., Zakharova G.R.

Πηγή: Almanac of Clinical Medicine; Vol 46, No 2 (2018); 184-193 ; Альманах клинической медицины; Vol 46, No 2 (2018); 184-193 ; 2587-9294 ; 2072-0505 ; 10.18786/2072-0505-2018-46-2

Θεματικοί όροι: hereditary autoinflammatory disease, PFAPA-syndrome, Marshall syndrome, children, наследственные аутовоспалительные заболевания человека, PFAPA-синдром, синдром Маршалла, дети

Περιγραφή αρχείου: application/pdf

Relation: https://almclinmed.ru/jour/article/view/798/817; https://almclinmed.ru/jour/article/downloadSuppFile/798/628; https://almclinmed.ru/jour/article/downloadSuppFile/798/629; https://almclinmed.ru/jour/article/view/798

Διαθεσιμότητα: https://almclinmed.ru/jour/article/view/798
https://doi.org/10.18786/2072-0505-2018-46-2-184-193

SYSTEMATIC JUVENILE ARTHRITIS: A MODERN VIEW ON PATHOGENESIS, DIAGNOSIS AND TREATMENT ; СИСТЕМНЫЙ ВАРИАНТ ЮВЕНИЛЬНОГО АРТРИТА: СОВРЕМЕННЫЙ ВЗГЛЯД НА ПАТОГЕНЕЗ, ДИАГНОСТИКУ И ЛЕЧЕНИЕ

Συγγραφείς: Игишева, Людмила Николаевна, Притчина, Светлана Сергеевна

Πηγή: Mother and Baby in Kuzbass; № 3 (2016): сентябрь; 4-9 ; Мать и Дитя в Кузбассе; № 3 (2016): сентябрь; 4-9 ; 2542-0968 ; 1991-010X

Θεματικοί όροι: hereditary autoinflammatory diseases, systematic juvenile arthritis, syhdrom Fanconi-Wissler, feber, аутовоспалительные заболевания, системный вариант ювенильного артрита, синдром Висслера-Фанкони, лихорадка

Περιγραφή αρχείου: application/pdf

Relation: http://mednauki.ru/index.php/MD/article/view/45/199; http://mednauki.ru/index.php/MD/article/view/45

Διαθεσιμότητα: http://mednauki.ru/index.php/MD/article/view/45

ROLE OF INTERLEUKIN 1 IN THE DEVELOPMENT OF HUMAN DISEASES ; Роль интерлейкина 1 в развитии заболеваний человека

Συγγραφείς: E. L. Nasonov, M. S. Eliseev, Е. Л. Насонов, М. С. Елисеев

Πηγή: Rheumatology Science and Practice; Vol 54, No 1 (2016); 60-77 ; Научно-практическая ревматология; Vol 54, No 1 (2016); 60-77 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20161

Θεματικοί όροι: ингибиторы интерлейкина 1, autoinflammatory diseases, cytokines, inflammasome, interleukin 1, interleukin 1 inhibitors, аутовоспалительные заболевания, цитокины, ин- фламмасома, интерлейкин 1

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2171/1392; McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3:e297. doi:10.1371/journal.pmed.0030297; Doria A, Zen M, Bettio S, et al. Autoinflammation and autoimmunity: Bridging the divide. Autoimm Rev. 2012;12:22-30. doi:10.1016/j.autrev.2012.07.018; Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003-18. doi:10.1016/j.immuni.2013.11.010; Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med. 2014 Dec 16;20 Suppl 1:S43-58. doi:10.2119/molmed.2014.00232; Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm. 2015;2015:194864. doi:10.1155/2015/194864; Насонов ЕЛ. Интерлейкин 1 и его роль в патологии человека. Терапевтический архив. 1987;(12):112-7 [Nasonov EL. Interleukin-1 and its role in human pathology. Terapevticheskii arkhiv. 1987;(12):112-7 (In Russ.)].; Schett G, Dayer J-M, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016 Jan;12(1):14-24. doi:10.1038/nrrheum.2016.166; Ильина АЕ, Станислав МЛ, Денисов ЛН, Насонов ЕЛ. Интерлейкин 1 как медиатор воспаления и терапевтическая мишень. Научно-практическая ревматология. 2011;49(5):62-71 [Il'ina AE, Stanislav ML, Denisov LN, Nasonov EL. Interleukin-1 as a mediator of inflammation and therapeutic target. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;49(5):62-71 (In Russ.)]. doi:10.14412/1995-4484-2011-1463; So A, Ives A, Joosten LAB, Busso N. Targeting inflammasomes in rheumatic diseases. Nat Rev Rheumatol. 2013;9:391-9. doi:10.1038/nrrheum.2013.61; Dinarello CA, van der Meer JWM. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25:469-84. doi:10.1016/j.smim.2013.10.008; Gabay G, Lamacchia C, Palme G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2014;6:232-41. doi:10.1038/nrrheum.2010.4; Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10:89-102. doi:10.1038/nri2691; Насонов ЕЛ, Денисов ЛН, Станислав МЛ. Интерлейкин 17 – новая мишень для антицитокиновой терапии иммуно-воспалительных ревматических заболеваний. Научно-практическая ревматология. 2013;51(5):545-52 [Nasonov EL, Denisov LN, Stanislav ML. Interleukin-17 is a new target for anti-cytokine therapy of immune inflammatory rheumatic diseases. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(5):545-52 (In Russ.)]. doi:10.14412/1995-4484-2013-1547; Singh RP, Hasan S, Sharma S, et al. Th17 cells in inflammation and autoimmunity. Autoimmun Rev. 2014;13:1174-81. doi:10.1016/j.autrev.2014.08.019; Spits H, Arti D, Colonna M, et al. Innate lymphoid cells – a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145-9. doi:10.1038/nri3365; Jimenez-Dalmaroni MJ, Gerswhin ME, Adamopoulos IE. The critical role of toll-like receptors – from microbial recognition to autoimmunity: A comprehensive review. Autoimmun Rev. 2016;15:1-8. doi:10.1016/j.autrev.2015.08.009; Afonina IS, Mü ller C, Martin SJ, Beyaert R. Proteolytic processing of Interleukin-1 family cytokines: variations on a common theme. Immunity. 2015;42:991-1004. doi:10.1016/j.immuni.2015.06.003; Guo H, Callaway JB, Jenny P-Y, Ting JP-Y. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21:677-87. doi:10.1038/nm.3893; Netea MG, van de Veerdonk FL, van der Meer JW, et al. Inflammasome-independent regulation of IL-1-family cytokines. Ann Rev Immunol. 2015;33:49-77. doi:10.1146/annurevimmunol-032414-112306; Schauer C, Janlo C, Munoz LE, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med. 2014;20:511-7. doi:10.1038/nm.3547; Joosten LA, Netea MG, Fantuzzi G, et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum. 2009;60(12):3651-62.; Chen C-J, Kono H, Golenbock D, et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med. 2007;13:851-6. doi:10.1038/nm1603; Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015;54:2134-44. doi:10.1093/rheumatology/kev269; Ter Haar NM, Oswald M, Jeyaratnan J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74:1636-44. doi:10.1136/annrheumdis-2015-207546; Touitou I, Kone-Paut I. Autoinflammatory diseases. Best Practice and Research. Clin Rheumatol. 2008;22:811-29. doi:10.1016/j.berh.2008.08.009; Stojanovic KS, Delmas Y, Torres PU, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant. 2012;27:1898-901. doi:10.1093/ndt/gfr528; Moser C, Pohl G, Haslinger I, et al. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transpl. 2009;24:676-8. doi:10.1093/ndt/gfn646; Meinzer U, Quartier P, Alexandra J-F, et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41:265-71. doi:10.1016/j.semarthrit.2010.11.003; Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr. 2008;167:695-6. doi:10.1007/s00431-007-0547-3; Mitroulis VP, Konstantinidis PT, Ritis K. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patien. Neth J Med. 2008;66:489-91.; Estublier KS, Stojanovic J-F, Broussolle BC, Seve P. Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. Joint Bone Spin. 2013;80:645-9. doi:10.1016/j.jbspin.2013.03.004; Akgul O, Kilic E, Kilic G, Ozgocmen S. Efficacy and safety of biologic treatments in familial Mediterranean fever. Amer J Med Sci. 2013;346:137-41. doi:10.1097/MAJ.0b013e318277083b; Hacihamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology. 2012;51:104. doi:10.1093/rheumatology/kes021; Mitroulis I, Skendros P, Oikonomou A, et al. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis. 2011;70:1347-8. doi:10.1136/ard.2010.146878; Brizi MG, Galeazzi M, Lucherini OM, et al. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Int Med. 2012;156:907-8. doi:10.7326/0003-4819-156-12-201206190-00027; Gattorno M, Obici L, Meini A. Efficacy and safety of canakinumab in patients with TNF receptor-associated periodic syndrome. Arthritis Rheum. 2012;64:749. doi:10.1136/annrheumdis-2012-eular.2361; Lopalco G, Rigant D, Vitale A, et al. Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol. 2015 Apr;34(4):807-9. doi:10.1007/s10067-014-2556-8. Epub 2014 Mar 11.; Cailliez M, Garaix F, Rousset-Rouviere C, et al. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherited Metab Dis. 2006;29:763. doi:10.1007/s10545-006-0408-7; Rigante D, Ansuini V, Bertoni B, et al. Treatment with anakinra in the hyperimmunoglobulinemia D periodic fever syndrome. Rheumatol Int. 2006;27:97-100. doi:10.1007/s00296-006-0164-x; Lequerre T, Vittecoq O, Pouplin S, et al. Mevalonate kinase deficiency syndrome with structural damage responsive to anakinra. Rheumatology. 2007;46:1860-2. doi:10.1093/rheumatology/kem258; Galeotti C, Meinzer U, Quartier P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology. 2012;51:1855-9. doi:10.1093/rheumatology/kes097; Bodar EJ, Kuijk LM, Drenth JPH, et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis. 2011;70:2155-8. doi:10.1136/ard.2011.149922; Bodar EJ, van der Hilst JCH, Drenth JPH, et al. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med. 2005;63:260-4.; Gomez AR, Couce ML, Garcia-Villoria J, et al. Clinical, genetic, and therapeutic diversity in 2 patients with severe mevalonate kinase deficiency. Pediatrics. 2012;129:e535-9. doi:10.1542/peds.2010-2192; Shendi HM, Walsh D, Edgar JDM. Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome. Rheumatol Int. 2012;32:249-51. doi:10.1007/s00296-009-1322-8; Teoh SRB, Sharma S, Hogan A, et al. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Brit J Ophthalmol. 2007;91:263-4. doi:10.1136/bjo.2006.0101477; Hedrich CM, Bruck N, Paul D, et al. Mutation negative familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies. Rheumatol Int. 2012;32:2629-36. doi:10.1007/s00296-011-2019-3; Goldbach-Mansky R, Dailey NJ, Canna SW, et al .Neonatalonset multisystem inflammatory disease responsive to interleukin-1β inhibition. New Eng J Med. 2006;355:581-92. doi:10.1056/NEJMoa055137; Gattorno M, Tassi S, Carta S, et al. Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 2007;56:3138-48. doi:10.1002/art.22842; Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62:258-67. doi:10.1002/art.25057; Lepore L, Paloni G, Caorsi R, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatrics. 2010;157:310-5. doi:10.1016/j.jpeds.2010.02.040; Miyamae T, Inaba Y, Ishimura G, et al. Effect of anakinra on arthropathy in CINCA/NOMID syndrome. Pediatr Rheumatol Online J. 2010 Mar 16;8:9. doi:10.1186/1546-0096-8-9; Lovell DL, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatalonset multisystem inflammatory disease. Arthritis Rheum. 2005;52:1283-6. doi:10.1002/art.20953; Aubert P, Suarez-Farinas M, Mitsui H, et al. Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1β. PLoS One. 2012;7(11):e49408. doi:10.1371/journal.pone.0049408. Epub 2012 Nov 30.; Balow JE Jr, Ryan JG, Chae JJ, et al. Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts. Ann Rheum Dis. 2013;72:1064-70. doi:10.1136/annrheumdis-2012-202082; Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 2012;64:2375-86. doi:10.1002/art.34409; Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med. 2003;348:2583-4. doi:10.1056/NEJM200306193482523; Rynne M, Maclean C, Bybee A, et al. Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis. 2006;65:533-4. doi:10.1136/ard.2005.038091; Stew BT, Fishpoo SJC, Owens D, Quine S. Muckle-Wells syndrome: a treatable cause of congenital sensorineural hearing loss. B-ENT. 2013;9:161-3.; Sabroe RA, Stokes CA, Parker LC, et al. Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1β and rapid response to anakinra. Clin Exp Dermatol. 2013;38:874-7. doi:10.1111/ced.12186; Enriquez R, Sirvent AE, Padilla S, et al. Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin-associated periodic syndrome. Renal Failure. 2013;35:738-41. doi:10.3109/0886022X.2013.790300; Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum. 2011;63:840-9. doi:10.1002/art.30149; Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical Features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 2004;50:607-12. doi:10.1002/art.20033; Metyas SK, Hoffman HM. Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud's disease. J Rheumatol. 2006;33:2085-7.; Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 2004;364:1779-85. doi:10.1016/S0140-6736(04)17401-1; Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, et al. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther. 2013;1:R64. doi:10.1186/ar4237; Kuemmerle-Deschner JB, Lohse P, Koet I, et al. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome-description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther. 2011;13:R196. doi:10.1186/ar3526; Sibley CH, Chioato A, Felix S, et al. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Ann Rheum Dis. 2015;74(9):1714-9. doi:10.1136/annrheumdis-2013-204877; Caorsi R, Lepore L, Zulian F, et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther. 2013;15:R33. doi:10.1186/ar4184; Imagawa T, Nishikomori R, Takada H, et al. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first openlabel, phase-3 pivotal study (24-week results). Clin Exp Rheum. 2013;31:302-9.; Mueller SM, Itin P, Haeuserman P. Muckle-wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory. Dermatology. 2011;223:113-8. doi:10.1159/000331580; Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. New Eng J Med. 2009;360:2416-25. doi:10.1056/NEJMoa0810787; Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther. 2011;1:R202. doi:10.1186/ar3535; Kuemmerle-Deschner JB, Ramos E, Blank N, et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrinassociated periodic syndrome (CAPS). Arthritis Res Ther. 2011;13: R34. doi:10.1186/ar3266; Kuemmerle-Deschner JB, Hachulla E, Cartwrigh R, et al. Twoyear results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70:2095-102. doi:10.1136/ard.2011.152728; Scarpioni R, Rigante D, Cantarini L, et al. Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab. Clin Rheumatol. 2014;34:1311-6. doi:10.1007/s10067-013-2481-2; Pazyar N, Feily A, Yaghoobi R. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr Clin Pharm. 2012;7:271-5. doi:10.2174/157488412803305821; Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) – a new autoinflammatory syndrome distinct from PAPA syndrome. J Amer Acad Derm. 2012;66:409-15. doi:10.1016/j.jaad.2010.12.025; Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Bri J Dermatol. 2009;161:1199-201. doi:10.1111/j.1365-2133.2009.09404.x; Dierselhuis MP, Frenkel J, Wulffra NM, Boelens JJ. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology. 2005;44:406-8. doi:10.1093/rheumatology/keh479; Schellevis MA, Stoffels M, Hoppenreijs EPAH, et al. Variable expression and treatment of PAPA syndrome. Ann Rheum Dis. 2011;70:1168-70. doi:10.1136/ard.2009.126185; Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Nat Acad Sci USA. 2003;100:13501-6. doi:10.1073/pnas.2135380100; Geusau A, Mothes-Luksch N, Nahavandi H, et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPAlike syndrome responding to canakinumab treatment. JAMA Dermatology. 2013;14:209-15. doi:10.1001/2013.jamadermatol.717; Kono H, Chen CJ, Ontiveros F, Rock KL. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest. 2010;120:1939-49. doi:10.1172/JCI40124; Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-41. doi:10.1038/nature04516; Rock KL, Kataoka H, Lai J-J. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9:13-23. doi:10.1038/nrheum.2012/143; Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, doubleblind trials and their initial extensions. Ann Rheum Dis. 2012;71:1839-48. doi:10.1136/annrheumdis-2011-200908; Wechalekar MD, Vinik O, Moi JUY. The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. J Rheumatol. 2014;92 (Suppl):15-25. doi:10.3899/jrheum.140458; Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov E. Canakinumab in patients with chronic tophaceous gout, resistant to current treatment options. Ann Rheum Dis. 2015;74(Suppl 2):541. doi:10.1136/annrheumdis-2015-eular.3451; Елисеев МС, Барскова ВГ, Насонов ЕЛ. Канакинумаб (ингибитор интерлейкина 1β) – прорыв в возможностях противовоспалительной терапии при подагре. Научно-практическая ревматология. 2013;51:428-31 [Eliseev MS, Barskova VG, Nasonov EL. Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(4):428-31 (In Russ.)]. doi:10.14412/1995-4484-2013-1255; Bardin T. Canakunumab for the patient with difficult-to-treat gouty arthritis: review of the clinical evidence. Joint Bone Spain. 2015;82:eS9-19. doi:10.1016/S1297-319X(15)30003-8; Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155-63. doi:10.1016/j.amjmed.2010.09.012; Neogi T. Gout. N Engl J Med. 2011;64:443-52. doi:10.1056/NEJMcp1001124; Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138-49. doi:10.1016/S0140-6736(11)60244-4; Negrovic PA. Is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheum. 2014;66:1405-13. doi:10.1002/art.38615; Maria ATJ, Le Quellec A, Jorgensen C, et al. Adult onset Still's disease (ASD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmune Rev. 2014;13:1149-59. doi:10.1016/j.autrev.2014.08.032; Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. ;201:1479-86. doi:10.1084/jem.20050473; Choi JH, Suh CH, Lee YM, et al Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol. 2003;30:2422-7.; Kotter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007;37:189-97. doi:10.1016/j.semarthrit.2007.04.002; Никишина ИП, Каледа МИ. Современная фармакотерапия системного ювенильного артрита. Научно-практическая ревматология. 2015;53:84-93 [Nikishina IP, Kaleda MI. Current pharmacotherapy for systemic juvenile arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53:84-93 (In Russ.)]. doi:10.14412/1995-4484-2015-84-93; Tarp S, Amarilyo G, Foeldvari I, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology. 2015. doi:10.1093/rheumatology/kev382. [Epub ahead of print].; Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs. 2008;17:349-59. doi:10.1517/13543784.17.3.349; Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302-8. doi:10.1136/ard.2007.076034; Bruck N, Suttorp M, Kabus M, et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17:23-7. doi:10.1097/RHU.0b013e318205092d; Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and longterm follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res Ther. 2011;13:R91. doi:10.1186/ar3366; Lo Gullo ACA, Pipitone N, Macchioni P, et al. Canakinumab in a case of Adult onset Still's disease: efficacy only on systemic manifestations. Joint Bone Spine. 2014;81:376-7. doi:10.1016/j.jbspin.2013.12.011; Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52:1794-803. doi:10.1002/art.21061; Giampietro C, Ridene M, Lequerre T, et al. Anakinra in adultonset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013;65:822-6. doi:10.1002/acr.21901; Kahn P, Cron RQ. Higher-dose anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol. 2013;40:743-4. doi:10.3899/jrheum.121098 110. Kalliolias GD, Georgiou PE, Antonopoulos IA, et al. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66:842-3. doi:10.1136/ard.2006.066381; Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still's disease. Semin Arthritis Rheum. 2012;42:201-5. doi:10.1016/j.semarthrit.2012.03.004; Lahiri M, Teng GG. A case of refractory adult-onset Still's disease treated with anakinra. Int J Rheum Dis. 2010;13:e36-41. doi:10.1111/j.1756-185X.2010.01474.x; Loh NK, Lucas M, Fernandez S, Prentice D. Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra. Intern Med J. 2012;42:1358-62. doi:10.1111/imj.12002; Naumann L, Feist E, Natusch A, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis. 2010;69:466-7. doi:10.1136/ard.2009.108068; Petryna O, Cush J, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still's disease. Ann Rheum Dis. 2012;71:2056-7. doi:10.1136/annrheumdis-2012-201409; Nordstrom D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol. 2012;39:2008-11. doi:10.3899/jrheum.111549; Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Design Dev Ther. 2014;8:2345-57.; De Koning HD, Bodar EJ, van der Meer JW, Simon A. Schnitzler syndrome: beyond the case reports: review and followup of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum. 2007;37:137-48. doi:10.1016/j.semarthrit.2007.04.001; Lipsker D, Veran Y, Grunenberger F, et al. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore). 2001;80:37-44. doi:10.1097/00005792-200101000-00004; De Koning HD. Schnitzler's syndrome: lessons from 281 cases. Clin Translat Allerg. 2014;4:41. doi:10.1186/2045-7022-4-41; Simon A, Asli B, Braun-Falco M, et al. Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68:562-8. doi:10.1111/all.12129; Pizzirani C, Falzoni S, Govoni M, et al. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxford). 2009;48:1304-8. doi:10.1093/rheumatology/kep222; De Koning HD, Schalkwijk J, Stoffels M. The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome. Arthritis Res Ther. 2015;17:187. doi:10.1186/s13075-015-0696-0; Krause K, Weller K, Stefaniak R, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy. 2012;67:943-50. doi:10.1111/j.1398-9995.2012.02843.x; De Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, et al. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Ann Rheum Dis. 2013;72:1634-8. doi:10.1136/annrheumdis-2012-202192; Besada E, Nossent H. Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review. Clin Rheumatol. 2010;29:567-71. doi:10.1007/s10067-010-1375-9; Schuster C, Kranke B, Aberer E, et al. Schnitzler syndrome: response to anakinra in two cases and a review of the literature. Int J Dermatol. 2009;48:1190-4. doi:10.1111/j.1365-4632.2009.04151.x; Ryan JG, de Koning HD, Beck LA, et al. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol. 2008;121:260-2. doi:10.1016/j.jaci.2007.09.021; De Koning HD, Bodar EJ, Simon A, et al. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis. 2006;65:542-4. doi:10.1136/ard.2005.045245; Martinez-Taboada VM, Fontalba A, Blanco R, Fernandez-Luna JL. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum. 2005;52:2226-7. doi:10.1002/art.21101; Pineton de Chambrun M, Wechsler B, Geri G, et al. New insights into the pathogenesis of Behcet's disease. Autoimmun Rev. 2012;11:687-98. doi:10.1016/j.autrev.2011.11.026; Hamzaoui K, Hamza M, Ayed K. Production of TNF-α and IL-1 in active Behcet's disease. J Rheumatol. 1990;17:1428-9.; Pay S, Erdem H, Pekel A, et al. Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behcet's disease. Does interleukin-1β play a major role in Behcet's synovitis? Rheumatol Int. 2006;26:608-13. doi:10.1007/s00296-005-0040-0; Castrichini M, Lazzerini PE, Gamberucci A, et al. The purinergic P2×7 receptor is expressed on monocytes in Behcet's disease and is modulated by TNF-α. Eur J Immunol. 2014;44:227-38. doi:10.1002/eji.201343353; Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol. 2015 Jul;34(7):1293-301. doi:10.1007/s10067-013-2443-8. Epub 2013 Dec 5.; Caso F, Rigante D, Vitale A, et al. Efficacy of anakinra in refractory Behcet's disease sacroiliitis. Clin Expl Rheumatol. 2014;324 (Suppl 84):S171.; Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease. Clin Rheumatol. 2010;29:209-10. doi:10.1007/s10067-009-1279-8; Botsios C, Sfriso P, Furlan A, et al. Resistant Behcet disease responsive to anakinra. Ann Int Med. 2008;149:284-6. doi:10.7326/0003-4819-149-4-200808190-00018; Emmi G, Silvestri E, Cameli AM, et al. Anakinra for resistant Behcet uveitis: why not? Clin Exp Rheumatol. 2013;31(Suppl 77):S152-3.; Cantarini L, Lopalco G, Caso F, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet's disease. Autoimm Rev. 2015;14:1-9. doi:10.1016/j.autrev.2014.08.008; Vitale A, Rigante D, Caso F, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcet's disease: a case series. Dermatology. 2014;228:211-4. doi:10.1159/000358125; Cantarini L, Vitale A, Borri M, et al. Successful use of canakinumab in a patient with resistant Behcet's disease. Clin Exp Rheumatol. 2012;30(Suppl 72):S115.; Gü l A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis. 2012;71:563-6. doi:10.1136/annrheumdis-2011-155143; Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab. Br J Dermatol. 2015;173:239-41. doi:10.1111/bjd.13614; Wendling D, Prati C, Aubin F. Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann Rheum Dis. 2012;71:1098-100. doi:10.1136/annrheumdis-2011-200743; Rech J, Manger B, Lang B, et al. Adult-onset Still's disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation. Rheumatol Int. 2012;32:1827-9. doi:10.1007/s00296-011-2020-x; Wu Y, Li H, Jiang Z, Lai Y. The interleukin-1 family: a key regulator in the pathogenesis of psoriasis. Austin J Clin Immunol. 2014;5:id1023.; Ariza M-E, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin Immunol. 2013;146:131-9. doi:10.1016/j.clim.2012.12.004; Anderson KS, Petersson S, Wong J, et al. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br J Dermatol. 2010;163:1085-9. doi:10.1111/j.1365-2133.2010.09990.x; Balato A, Schiattarella M, Lembo S, et al. Interleukin-1 family members are enhanced in psoriasis and suppressed by vitamin D and retinoic acid. Arch Dermatol Res. 2013;305:255-62. doi:10.1007/s00403-013-1327-8; Johnston A, Xing X, Guzman AM, et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. 2011;186:2613-22. doi:10.4049/jimmunol.1003162; Tamilselvi E, Haripriya D, Hemamalini M, et al. Association of disease severity with IL-1 levels in methotrexate-treated psoriasis patients. Scand J Immunol. 2013;78:545-53. doi:10.1111/sji.12117; Dungan LS, Mills KH. Caspase-1-processed IL-1 family cytokines play a vital role in driving innate IL-17. Cytokine. 2011;56:126-32. doi:10.1016/j.cyto.2011.07.007; Sutton CE, Lalor SJ, Sweeney CM, et al. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009;31:331-41. doi:10.1016/j.immuni.2009.08.001; Groves RW, Mizutani H, Kieffer JD, Kupper TS. Inflammatory skin disease in transgenic mice that express high levels of interleukin 1 alpha in basal epidermis. Proc Natl Acad Sci USA. 1995;92:11874-8. doi:10.1073/pnas.92.25.11874; Groves RW, Rauschmayr T, Nakamura K, et al. Inflammatory and hyperproliferative skin disease in mice that express elevated levels of the IL-1 receptor (type I) on epidermal keratinocytes. Evidence that IL-1-inducible secondary cytokines produced by keratinocytes in vivo can cause skin disease. J Clin Invest. 1996;98:336-44. doi:10.1172/JCI118797; Shepherd J, Little MC, Nicklin MJ. Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. J Invest Dermatol. 2004;122:665-9. doi:10.1111/j.0022-202X.2004.22305.x; Mee JB, Johnson CM, Morar N, et al. The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. Am J Pathol. 2007;171:32-42. doi:10.2353/ajpath.2007.061067; Pontifex EK, Gerlag DM, Gogarty M, et al. Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy: a single centre, open-label study. Arthritis Res Ther. 2011;13:R7. doi:10.1186/ar3228; Jung N, Hellmann M, Hoheisel R, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol. 2011;29:1169-73. doi:10.1007/s10067-010-1504-5; Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-204. doi:10.1002/1529-0131(199812)41:123.0.CO;2-2; Cohen S, Moreland BW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004;63:1062-8. doi:10.1136/ard.2003.016014; Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebocontrolled trial. Arthritis Rheum. 2002;46:614-24. doi:10.1002/art.10141; Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36:1118-25. doi:10.3899/jrheum.090074; Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (rmetHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48:927-34. doi:10.1002/art.10870; Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology. 2001;41:972-80. doi:10.1093/rheumatology/41.9.972; Cunnane G, Madigan A, Murphy E, et al. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology. 2001;40:62-9. doi:10.1093/rheumatology/40.1.62; Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol. 2004;31:1103-11.; Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 2000;43:1001-9. doi:10.1002/1529-0131(200005)43:53.0.CO;2-P; Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000;191:313-20. doi:10.1084/jem.191.2.313; Wood DD, Ihrie EJ, Dinarello CA, Cohen PL. Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum. 1983;26:975-83. doi:10.1002/art.1780260806; Koch AE, Kunkel SL, Chensue SW, et al. Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin Immunol Immunopathol. 1992;65:23-9. doi:10.1016/0090-1229(92)90243-H; Firestein GS, Berger AE, Tracey DE, et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol. 1992;149:1054-62.; Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum. 1996;39:797-809. doi:10.1002/art.1780390513; Zwerina J, Hayer S, Tohidast-Akrad M, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 2004;50:277-90. doi:10.1002/art.11487; Choulaki C, Papadaki G, Repa A, et al. Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis. Arthritis Res Ther. 2015;17:257. doi:10.1186/s13075-0775-2; Nam JL, Ramino S, Gaujoux-Viala C, et al. Extended report: Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516-28. doi:10.1136/annrheumdis-2013-204577; Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Protocol). Cochrane Database of Systematic Reviews. 2009;2:CD007848. doi:10.1002/14651858.CD007848; Alten R, Gomez-Reino J, Durez P, et al. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. BMC Musculoskelet Disord. 2011;12:153. doi:10.1186/1471-2474-12-153; Demin I, Hamren B, Luttringer O, et al. Longitudinal modelbased meta-analysis in rheumatoid arthritis: an application toward model-based drug development. Clin Pharm Ther. 2012;92:352-9. doi:10.1038/clpt.2012.69; Orlowsky EW, Kraus VB. The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive. J Rheumatol. 2015;42:363-71. doi:10.3899/jrheum.140382; Wang X, Hunter D, Xu J, Ding C. Metabolic triggered inflammation in osteoarthritis RSS Download PDF Get rights and content. Osteoarthr Cartilage. 2015;23:22-30. doi:10.1016/j.joca.2014.10.002; Liu-Bryan R, Terkeltaub R. Emerging regulators of the inflammatory process in osteoarthritis. Nat Rev Rheumatol. 2015;11:35-44. doi:10.1038/nrrheum.2014.162; Kusano K, Miyaura C, Inada M, et al. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology. 1998;139:1338-45. doi:10.1210/endo.139.3.5818; Goldring MB, Birkhead JR, Suenet LF, et al. Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. J Clin Invest. 1994;94:2307-16. doi:10.1172/JCI117595; Tyler JA. Articular cartilage cultured with catabolin (pig interleukin 1) synthesizes a decreased number of normal proteoglycan molecules. Biochem J. 1985;227:869-78. doi:10.1042/bj2270869; Attur MG, Patel IR, Patel RN, et al. Autocrine production of IL-1β by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8. Proc Assoc Am Physicians. 1998;110:65-72.; Pelletier JP, Caron JP, Evans C, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum. 1997;40:1012-9. doi:10.1002/art.1780400604; Fernandes J, Tardif G, Martel-Pelletier J, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol. 1999;154:1159-69. doi:10.1016/S0002-9440(10)65368-0; Attur M, Wang H-Y, Kraus VB, et al. Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations. Ann Rheum Dis. 2010;69:856-61. doi:10.1136/ard.2009.113043; Kerkhof HJ, Doherty M, Arden NK, et al. Large-scale metaanalysis of interleukin-1 beta and interleukin-1 receptor antagonist polymorphisms on risk of radiographic hip and knee osteoarthritis and severity of knee osteoarthritis. Osteoarthr Cartil. 2011;19:265-71. doi:10.1016/j.joca.2010.12.003; Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009;61:344-52. doi:10.1002/art.24096; Cohen SB, Proudman S, Kivitz AJ, et al. A randomized, doubleblind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of knee. Arthritis Res Ther. 2011;13:R125. doi:10.1186/ar3430 194. Heiland GR, Aigner E, Dallos T, et al. Synovial immunopathology in haemochromatosis arthropathy. Ann Rheum Dis. 2010;69:1214-9. doi:10.1136/ard.2009.120204; Latourte A, Frazier A, Briere C, et al. Interleukin-1 receptor antagonist in refractory haemochromatosis-related arthritis of the hands. Ann Rheum Dis. 2013;72:783-4. doi:10.1136/annrheumdis-2012-202738; Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999; 340: 115. doi:10.1056/NEJM199901143400207; Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95. doi:10.1056/NEJMra043430; Libby P, Ridker PM, Hansson GK. Progresss and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-25. doi:10.1038/nature10146; Skeoch S, Bruce IA. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015 Jul;11(7):390-400. doi:10.1038/nrrheum.2015.40. Epub 2015 Mar 31.; Nurmohamed NT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11:693-704. doi:10.1038/nrrheum.2015.112; Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-61. doi:10.1038/nature08938; Rajamaki K, Lappalainen J, Oorni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One. 2010;5:e11765. doi:10.1371/journal.pone.0011765; Xiao H, Lu M, Lin TY, et al. Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation. 2013;128:632-42. doi:10.1161/CIRCULATIONAHA.113.002714; Van Tassel BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation. 2013;128:1910-3. doi:10.1161/CIRCULATION.113.003199; Roubille F, Busseuil D, Shi Y. The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis. 2014;236:277-85. doi:10.1016/j.atherosclerosis.2014.07.012; Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory; Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605. doi:10.1016/j.ahj.2011.06.012; Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126:2739-48. doi:10.1161/CIRCULATIONAHA.112.122556; The Interleukin 1 genetics Consortium. Cardiometabolic effects of genetic upregulation of the interleukin 1receptor antagonists: a Mendelian randomization analysis. Lancet Diabetes Endocrinol. 2015;3:243-53. doi:10.1016/S2213-8587(15)00034-0; Rader DJ. IL-1 and atherosclerosis: a murine twist to an evolving human story. J Clin Invest. 2012;122:27-30. doi:10.1172/JCI61163; Frangogiannis N. Interleukin-1 in cardiac injury, repair, and remodeling: pathophysiologic and translational concepts. Discoveries J. 2015;3:e41. doi:10.15190/d.2015.33; Lugrin J, Parapanov R, Rosenblatt-Velin N, et al. Cutting edge: IL-1alpha is a crucial danger signal triggering acute myocardial inflammation during myocardial infarction. J Immunol. 2015;194:499-503. doi:10.4049/jimmunol.1401948; Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010;105:1371-7. doi:10.1016/j.amjcard.2009.12.059; Abbate A, van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study. Am J Cardiol. 2013;111:1394-400. doi:10.1016/j.amjcard.2013.01.287; Abbate A, Kontos MC, Abouzaki NA, et al. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol. 2015;115:288-92. doi:10.1016/j.amjcard.2014.11.003; Morton AC, Rothman AM, Greenwood JP, et al. The effect of Interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36:377-4. doi:10.1093/eurheartj/ehu272; Van Tassell BW, Arena R, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014;113:321-27. doi:10.1016/j.amjcard.2013.08.047; Herder C, Dalmas E, Boni-Schnetzler M, Donath MY. The IL-1 pathway in type 2 diabetes and cardiovascular complications Trends Endocrinol Metab. 2015;26:551-63. doi:10.1016/j.tem.2015.08.001; Masters, SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol. 2010;11:897-904. doi:10.1038/ni.1935; Herder C, Carstensen M, Ouwens DM, et al. Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obes Metab. 2013;15:39-50. doi:10.1111/dom.12155; Carstensen M, Herder C, Kivimä ki M, et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes. 2010;59:1222-7. doi:10.2337/db09-1199; Patti G, Di Sciascio G, D'Ambrosio A, et al. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2002;89:372-6. doi:10.1016/S0002-9149(01)02254-8; Blankenberg S, Zeller T, Saarela O, et al; MORGAM Project. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation. 2010;121:2388-97. doi:10.1161/CIRCULATIONAHA.109.901413; Ligthart S, Sedaghat S, Ikram MA, et al. EN-RAGE: a novel inflammatory marker for incident coronary heart disease. Arterioscler Thromb Vasc Biol. 2014;34:2695-9. doi:10.1161/ATVBAHA.114.304306; Looker HC, Colombo M, Agakov F, et al; SUMMIT Investigators. Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. Diabetologia. 2015;58:1363-71. doi:10.1007/s00125-015-3535-6; Hensen J, Howard CP, Walter V, Thuren T. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 2013;39:524-31. doi:10.1016/j.diabet.2013.07.003; Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517-26. doi:10.1056/NEJMoa065213; Larsen CM, Faulenbach M, Vaag A, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009;32:1663-8. doi:10.2337/dc09-0533; Van Asseldonk EJ, Stienstra R, Koenen TB, et al. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2011;96:2119-26. doi:10.1210/jc.2010-2992; Van Asseldonk EJ, van Poppel PC, Ballak DB, et al. One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus. Clin Immunol. 2015;160:155-62. doi:10.1016/j.clim.2015.06.003; Sloan-Lancaster J, Abu-Raddad E, Polzer J, et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care. 2013;36:2239-46. doi:10.2337/dc12-1835; Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012;35:1654-62. doi:10.2337/dc11-2219; Rissanen A, Howard CP, Botha J, Thuren T; Global Investigators. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab. 2012;14:1088-96. doi:10.1111/j.1463-1326.2012.01637.x; Stahel M, Becker M, Graf N, Michels S. Systemic interleukin 1β inhibition in proliferative diabetic retinopathy: A Prospective Open-Label Study Using Canakinumab. Retina. 2016 Feb;36(2):385-91. doi:10.1097/IAE.0000000000000701; Timper K, Seelig E, Tsakiris DA, Donath MY. Safety, pharmacokinetics, and preliminary efficacy of a specific anti-IL-1alpha therapeutic antibody (MABp1) in patients with type 2 diabetes mellitus. J Diabetes Complications. 2015 Sep-Oct;29(7):955-60. doi:10.1016/j.jdiacomp.2015.05.019. Epub 2015 Jun 3.; Herder C, Bongaerts BW, Rathmann W, et al. Association of subclinical inflammation with polyneuropathy in the older population: KORA F4 study. Diabetes Care. 2013;36:3663-70. doi:10.2337/dc13-0382; Agrawal NK, Kant S. Targeting inflammation in diabetes: newer therapeutic options. World J Diabetes. 2014 Oct 15;5(5):697-710. doi:10.4239/wjd.v5.i5.697; Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378:1015-26. doi:10.1016/S0140-6736(11)60988-4; Rovina N, Koutsoukou A, Koulouris NG. Inflammation and immune response in COPD: where do we stand? Mediators Inflamm. 2013;2013:413735. doi:10.1155/2013/413735. Epub 2013 Jul 15; Birrell MA, Eltom S. The role of the NLRP3 inflammasome in the pathogenesis of airway disease. Pharmacol Ther. 2011;130:364-70. doi:10.1016/j.pharmthera.2011.03.007; Rogliani P, Calzetta L, Ora J, Metara MG. Canakinumab for the treatment of chronic obstructive pupmonary disease. Pulm Pharmacol Ther. 2015;31:15-27. doi:10.1016/j.pupt.2015.01.005; Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009;11:81-9.; Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999;100:2124-6. doi:10.1161/01.CIR.100.21.2124; Ikonomidis I, Tzortzis S, Lekakis J, et al. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009;95:1502-7. doi:10.1136/hrt.2009.168971; Ikonomidis I, Lekakis JP, Nikolaou M, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117:2662-9. doi:10.1161/CIRCULATIONAHA.107.731877; Ikonomidis I, Tzortzis S, Andreadou I, et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014;7:619-28. doi:10.1161/CIRCIMAGING.113.001193; Abbate A, Canada JM, van Tassel BW, et al. Interleukin-1 blockade in rheumatoid arthritis and heart failure: A missed opportunity? Int J Cardiol. 2014;171:e125-6. doi:10.1016/j.ijcard.2013.12.07; Arena R, Myers J, Guazzi M. The clinical and research applications of aerobic capacity and ventilatory efficiency in heart failure: an evidence-based review. Heart Fail Rev. 2008;13:245-69. doi:10.1007/s10741-007-9067-5; Swank AM, Horton J, Fleg JL, et al. Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training. Circ Heart Fail. 2012;5:579-85. doi:10.1161/CIRCHEARTFAILURE.111.965186; Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol. 2005;95:9C-16C. doi:10.1016/j.amjcard.2005.03.007; Кондратьева ЛВ, Попкова ТВ, Насонов ЕЛ. Метаболический синдром при ревматоидном артрите. Научно-практическая ревматология. 2013;51:302-12 [Kondratyeva LV, Popkova TV, Nasonov EL. Metabolic syndrome in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51:302-12 (In Russ.)]. doi:10.14412/1995-4484-2013-1506; Ruscitti P, Cipriani P, Di Benedetto P. Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotidebinding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. Clin Exp Immunol 2015;182:35-44. doi:10.1111/cei.12667; Ruscitti P, Cipriani P, Cantarini L, et al. Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: a two case report and review of literature. J Med Case Rep. 2015 Jun 2;9:123. doi:10.1186/s13256-015-0603-y; Crisan TO, Cleophas MCP, Oosting M, et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann Rheum Dis. 2015 Feb 3. doi:10.1136/annrheumdis-2014-206564. [Epub ahead of print].; Stern SM, Ferguson PJ. Autoinflammatory bone diseases. Rheum Dis Clin North Am. 2013;39:735-49. doi:10.1016/j.rdc.2013.05.002; Xiao J, Fu C, Zhang X, et al. Soluble monosodium urate, but not its crystal, induces toll like receptor 4-dependent immune activation in renal mesangial cells. Mol Immunol. 2015;66:310-8. doi:10.1016/j.molimm.2015.03.250; Panoulas VF, Douglas KM, Milionis HJ, et al. Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis. J Hum Hypertens. 2008;22:177-82. doi:10.1038/sj.jhh.1002298; Daoussis D, Panoulas V, Toms T, et al. Uric acid is a strong independent predictor of renal dysfunction in patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11:R116. doi:10.1186/ar2775; Panoulas V, Milionis HJ, Douglas KM, et al. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis. Rheumatology (Oxford). 2007;46:1466-70. doi:10.1093/rheumatology/kem159; Daoussis D, Kitas GD. Uric acid and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1354-5. doi:10.1093/rheumatology/keq388; Petsch C, Araujio E, Englbrecht M, et al. Prevalence of monosodium urate deposits in a population of rheumatoid arthritis patients with hyperuricemia. Semin Arthritis Rheum. 2015 Dec 2. doi:10.1016/j.semarthrit.2015.11.014. [Epub ahead of print].; Denoble AE, Huffman KM, Stabler TV, et al. Uric acid a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Nat Acad Sci USA. 2011;108:2088-93. doi:10.1073/pnas.1012743108; Cicero AF, Salvi P, D'Addato S, et al. Brisighella Heart Study. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hypertens. 2014;32:57-64. doi:10.1097/HJH.0b013e328365b916; Athyros VG, Mikhailidis DP. Uric acid, chronic kidney disease and type 2 diabetes: A cluster of vascular risk factors. J Diabet Compl. 2014;28:122-3. doi:10.1016/j.jdiacomp.2013.11.012; Gustafsson D, Unwin R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013;14:164. doi:10.1186/1471-2369-14-164; Chaudhary K, Malhotra K, Sowers J, et al. Uric acid – key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med. 2013;3:208-20. doi:10.1159/000355405; De Bosch BJ, Kluth O, Fujiwara H, et al. Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nat Commun. 2014;5:4642. doi:10.1038/ncomms5642; Breshihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2001 Apr;30(5 Suppl 2):17-20. doi:10.1053/sarh.2001.23701; Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016 Mar;55(3):523-34. doi:10.1093/rheumatology/kev374. Epub 2015 Oct 21.; Dinarello CA, Simon A, Meer van der JWS. Treating inflammation by blocking interleukin-1 in a broad spectrum of disease. Nat Rev Drug Discov. 2012;11:633-52. doi:10.1038/nrd3800; Blech M, Peter D, Fischer P, et al. One target-two different binding model: structural insight into gevolkizumab and canakinumab interactions to interleukin-1β. J Mol Biol. 2013;425:94-111. doi:10.1016/j.jmb.2012.09.021; Coleman KM, Gudjonsson JE, Stecher M. Open-label trial of MABp1, a true human monoclonal antibody targeting interleukin 1β, for the treatment of psoriasis. JAMA Dermatol. 2015;151:555-6. doi:10.1001/jamadermatol.2014.5391; Shao B-Z, Xu Z-Q, Han B-Z, et al. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6: article 262. doi:10.3389/fpharm.2015.00262; Frenzel E, Wrenger S, Immenschuh S, et al. Acute-phase protein α1-antitrypsin – a novel regulator of angiopoietin-like protein 4 transcription and secretion. J Immunol. 2014;192:5354-62. doi:10.4049/jimmunol.1400378; Joosten LA, Crisan TO, Azam T, et al. α-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra. Ann Rheum Dis. 2015 Jul 14. doi:10.1136/annrheumdis-2014-206966. [Epub ahead of print].; Edwards NL, So A. Emerging therapies for gout. Rheum Dis Clin N Amer. 2014;40:375-87. doi:10.1016/j.rdc.2014.01.013; Giamarellos-Bourboulis EJ, Mouktarond M, Bodar E, et al. Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1β by mononuclear cells through a caspase 1-mediated process. Ann Rheum Dis. 2009;68:273-8. doi:10.1136/ard.2007.082222

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2171
https://doi.org/10.14412/1995-4484-2016-60-77

SYSTEMATIC JUVENILE ARTHRITIS: A MODERN VIEW ON PATHOGENESIS, DIAGNOSIS AND TREATMENT

Πηγή: Мать и дитя в Кузбассе, Vol 17, Iss 3, Pp 4-9 (2016)

Θεματικοί όροι: аутовоспалительные заболевания, системный вариант ювенильного артрита, синдром висслера-фанкони, лихорадка, Pediatrics, RJ1-570, Gynecology and obstetrics, RG1-991

Relation: http://mednauki.ru/index.php/MD/article/view/45; https://doaj.org/toc/1991-010X; https://doaj.org/toc/2542-0968; https://doaj.org/article/d0a32f6ca3394b0dbc5b39c9941b19af

Διαθεσιμότητα: https://doaj.org/article/d0a32f6ca3394b0dbc5b39c9941b19af

СИСТЕМНЫЙ ВАРИАНТ ЮВЕНИЛЬНОГО АРТРИТА: СОВРЕМЕННЫЙ ВЗГЛЯД НА ПАТОГЕНЕЗ, ДИАГНОСТИКУ И ЛЕЧЕНИЕ

Συγγραφείς: ИГИШЕВА Людмила Николаевна, ПРИТЧИНА Светлана Сергеевна

Θεματικοί όροι: аутовоспалительные заболевания, системный вариант ювенильного артрита, синдром ВисслераФанкони, лихорадка

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/sistemnyy-variant-yuvenilnogo-artrita-sovremennyy-vzglyad-na-patogenez-diagnostiku-i-lechenie
http://cyberleninka.ru/article_covers/16912970.png

BEHCET'S DISEASE IN CHILDREN: RUSSIAN EXPERIENCE ; Болезнь Бехчета у детей (российский опыт)

Συγγραφείς: N. N. Kuzmina, E. S. Fedorov, S. O. Salugina, Z. S. Alekberova, Н. Н. Кузьмина, Е. С. Федоров, С. О. Салугина, З. С. Алекберова

Πηγή: Rheumatology Science and Practice; Vol 53, No 3 (2015); 312-318 ; Научно-практическая ревматология; Vol 53, No 3 (2015); 312-318 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20153

Θεματικοί όροι: детский возраст, systemic vasculitis, autoinflammatory diseases, childhood, системный васкулит, аутовоспалительные заболевания

Relation: Алекберова ЗС. Болезнь Бехчета. Москва; 2007 [Alekberova ZS. Bolezn' Bekhcheta [Behcet’s disease]. Moscow; 2007].; Petty R, Cassidy J. Behcet's disease and other vasculitides. In: Textbook of pediatric rheumatology. Cassidy J.T. et al., editors. 4th ed. 2001. P. 629–38.; Al-Mosawi ZS, Madan W, Fareed E. Pediatric-onset Behcet disease in Bahraine: Report of nine cases and literature review. Ann Iran Med. 2012;215(8):485–7.; Кузьмина НН, Салугина СО, Федоров ЕС. Аутовоспалительные заболевания и синдромы. Учебно- методическое пособие. Москва: ИМА-ПРЕСС; 2012 [Kuz'mina NN, Salugina SO, Fedorov ES. Autovospalitel'nye zabolevaniya i sindromy. Uchebno-metodicheskoe posobie [Autoinflammatory diseases and syndromes. Training handbook]. Moscow: IMA-PRESS; 2012].; Измаилова ФИ, Алекберова ЗС Болезнь Бехчета: демографические и генетические аспекты. (Обзор литературы). Современная ревматология. 2014;(1):53–8 [Izmailova FI, Alekberova ZS. Behcet's disease: demographic and genetic aspects (a literature review). Sovremennaya evmatologiya = Modern Rheumatology Journal. 2014;(1):53–8 (In Russ.)]. doi:10.14412/1996-7012-2014-1-53-58; Kö se O. Development of immunopathogenesis strategies to treat Behcet`s disease. Path Res Intern. 2012. Art. ID 261989. doi:10.1155/2012/261989; Kone-Paut I, Sanches E, Le Quellec, et al. Autoinflammatory gene mutation in Behcet's disease. Ann Rheum Dis. 2007;66:832–4. doi:10.1136/ard.2006.068841; Menton M, LaValley M, Maldini C, et al. HLA-B51/B5 and the risk of Behcet's disease: A systematic review and meta-analysis of case-control genetic association studies. Art Rheum. 2009;61:1287–96. doi:10.1002/art.24642; International Study group Behcet's disease: Criteria for diagnosis of Behcet's. Lancet. 1990;335:1078–80.; Kone-Paut I, Darce-Bello M, Shahram F, et al. Registries in rheumatological and musculoskeletal condition. Pediatric Behcet's disease: an international cohort study of 110 patients. One-year follow-up study. Rheumatology. 2011:50:184–8. doi:10.1093/rheumatology/ceq324; Baharbi SA, Al-Mayzyed A, Al-Balaa S, et al. Juvenile Behcet's disease in Arab children. Clin Exp Rheum. 1996;14:502–5.; Uziel Y, Brik R, Padeh S, et al. Juvenile Bechcet's disease in Israel. Clin Exp Rheum. 1998;16:331–5.; Edem B, Onur C, Ozen S. Clinical features of pediatric Behcet's disease. J Pediatr Ophtalmol Strabismus. 1998;35:159–61.; Seyahi E, Ozdogan H, Virdakul S, et al. The disease presentation and outcome in children with Behcet disease. Ann Rheum Dis. 2005;64:879.; Kone-Paut I, Jurdakul S, Bahabri SA, et al. Clinical features of Behcet's disease in children: An International collaborative study of 86 cases. J Pediatr. 1998;132:721–5. doi:10.1016/S0022- 3476(98)70368-3; Sarica R, Azizlerrh G, Kose A, et al. Juvenile Behcet's disease among 1784 Turkish Behcet's patients. J Dermatol. 1996;35:108–11.; Friling R, Rramer M, Snir M, et al. Clinical course and outcome of uveitis in children. JAPOS. 2005;9:349–82. doi:10.1016/j.jaapos. 2005.04.005; Fudjikawa S, Snemitsu T. Behcet's disease in children: nationwide retrospective survey in Japan. Acta Pediatr Jpn. 1997;39:285–9. doi:10.1111/j.1442-200X.1997.tb03601.x; Kramer M, Amer R, Mukamel M, et al. Uveitis in juvenile Behcet's disease: clinical course and visual outcome compared with adult patients. Eye (London). 2009 Nov;23(11):2034–41. doi:10.1038/eye.2008.397. Epub 2009 Jan 16.; Karinvacoglu J, Borlu M, Token S, et al. Demographic and clinical properties of juvenile-onset Behcet's disease: a controlled multicenter study. J Am Acad Dermatol. 2008;58:1584–97.; Kim D, Chang SN, Bang D, et al. Clinical analysis of 40 cases of childhood-onset Behcet's disease. Pediatr Dermatol. 1994;11:95–101. doi:10.1111/j.1525-1470.1994.tb00559.x; Vaipoulos G, Kaklamani VG, Markomichelakis N, et al. Clinical features of juvenile Adamnitiades-Behcet's disease in Greece. Clin Exp Rheumatol. 1999;17:256–9.; Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. 2-е изд. Москва: ГЭОТАР-Медиа; 2010. С. 634–48 [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical guidelines]. 2nd ed. Moscow: GEOTAR-Media; 2010. P. 634–48].; Ozen S, Petty E. Behcet disease. In: Textbook of pediatric rheumatology. Cassidy J.T. et al., editors. 6th ed. Philadelphia: Elsevier Saunders; 2011. P. 552–8.; Сигидин ЯА. Синдром Бехчета. В кн.: Диффузные болезни соединительной ткани. Руководство для врачей. Москва: Медицина; 2004. С. 616–27 [Sigidin YaA. Behcet’s sindrom. In: Diffuznye bolezni soedinitel'noi tkani. Rukovodstvo dlya vrachei [Diffuse connective tissue disease. Guide for physicians]. Moscow: Meditsina; 2004. P. 616–27].; Bhakta B, Hamuryudan V, Brennan P, et al. Assessment of disease activity in Behcet's disease. In: Wechsler B, Godeau P, editors. Behcet's disease. Amsterdam: Elsevier Science; 1993. P. 235.; Bhakta BB, Brennan P, James TE,et al. Behcet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology. 1999;38:728–33. doi:10.1093/rheumatology/ 38.8.728; Hatemi G, Silman A, Bang D. EULAR recommendation for the management of Behcet's disease. Ann Rheum Dis. 2008;67:1656–62. doi:10.1136/ard.2007.080432; Yazini H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322:281–5. doi:10.1056/NEJM199002013220501; Barnes CG. Treatment of Behcet's syndrome. J Rhematology. 2006;45:245–7. doi:10.1093/ rhematology/key257; Melikoglu M, Fresco I, Mat C, et al. Short-term trial of etanercept in Behcet's: a double-blind placebo controlled study. J Rhematol. 2005;32:98–105.

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2095
https://doi.org/10.14412/1995-4484-2015-312-318

БОЛЕЗНЬ БЕХЧЕТА У ДЕТЕЙ (РОССИЙСКИЙ ОПЫТ)

Συγγραφείς: КУЗЬМИНА Н.Н., ФЕДОРОВ Е.С., САЛУГИНА С.О., АЛЕКБЕРОВА З.С.

Θεματικοί όροι: БОЛЕЗНЬ БЕХЧЕТА,СИСТЕМНЫЙ ВАСКУЛИТ,АУТОВОСПАЛИТЕЛЬНЫЕ ЗАБОЛЕВАНИЯ,ДЕТСКИЙ ВОЗРАСТ,BEHCET'S DISEASE,SYSTEMIC VASCULITIS,AUTOINFLAMMATORY DISEASES,CHILDHOOD

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/bolezn-behcheta-u-detey-rossiyskiy-opyt
http://cyberleninka.ru/article_covers/16091215.png

ХРОНИЧЕСКИЙ РЕЦИДИВИРУЮЩИЙ МУЛЬТИФОКАЛЬНЫЙ ОСТЕОМИЕЛИТ В ПРАКТИКЕ РЕВМАТОЛОГА (СЕМЕЙНЫЕ НАБЛЮДЕНИЯ)

Συγγραφείς: ШАЯХМЕТОВА РУШАНА УЛЬФАТОВНА, СИГИДИН Я.А., КУЗЬМИНА Н.Н., СМИРНОВ А.В.

Θεματικοί όροι: АУТОВОСПАЛИТЕЛЬНЫЕ ЗАБОЛЕВАНИЯ,ХРОНИЧЕСКИЙ РЕЦИДИВИРУЮЩИЙ МУЛЬТИФОКАЛЬНЫЙ ОСТЕОМИЕЛИТ,AUTOINFLAMMATORY DISEASES,CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/hronicheskiy-retsidiviruyuschiy-multifokalnyy-osteomielit-v-praktike-revmatologa-semeynye-nablyudeniya
http://cyberleninka.ru/article_covers/16091203.png

СЕМЕЙНЫЙ СЛУЧАЙ СИНДРОМА MUCKLE-WELLS В РОССИЙСКОЙ ПОПУЛЯЦИИ: ПЕРВЫЕ УСПЕХИ ТЕРАПИИ ИНГИБИТОРОМ ИНТЕРЛЕЙКИНА 1 КАНАКИНУМАБОМ

Συγγραφείς: Салугина, Светлана, Федоров, Е., Захарова, Е., Евсикова, М.

Θεματικοί όροι: АУТОВОСПАЛИТЕЛЬНЫЕ ЗАБОЛЕВАНИЯ, КРИОПИРИН-АССОЦИИРОВАННЫЙ ПЕРИОДИЧЕСКИЙ СИНДРОМ, СИНДРОМ MUCKLE-WELLS, СЕМЕЙНЫЙ СЛУЧАЙ, ИНГИБИТОРЫ ИНТЕРЛЕЙКИНА 1, КАНАКИНУМАБ, ЛЕЧЕНИЕ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/semeynyy-sluchay-sindroma-muckle-wells-v-rossiyskoy-populyatsii-pervye-uspehi-terapii-ingibitorom-interleykina-1-kanakinumabom
http://cyberleninka.ru/article_covers/15713517.png

СЛУЧАЙ ПЕРИОДИЧЕСКОЙ БОЛЕЗНИ У РЕБЕНКА РАННЕГО ВОЗРАСТА

Συγγραφείς: Бондаренко, К.

Θεματικοί όροι: АУТОВОСПАЛИТЕЛЬНЫЕ ЗАБОЛЕВАНИЯ,ПЕРИОДИЧЕСКАЯ БОЛЕЗНЬ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/sluchay-periodicheskoy-bolezni-u-rebenka-rannego-vozrasta
http://cyberleninka.ru/article_covers/15573969.png

Системный вариант ювенильного артрита: современный взгляд на патогенез, диагностику и лечение

Πηγή: Мать и дитя в Кузбассе.

Θεματικοί όροι: аутовоспалительные заболевания, системный вариант ювенильного артрита, синдром ВисслераФанкони, лихорадка, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article_covers/16912970.png
http://cyberleninka.ru/article/n/sistemnyy-variant-yuvenilnogo-artrita-sovremennyy-vzglyad-na-patogenez-diagnostiku-i-lechenie

Применение ингибитора интерлейкина 1 канакинумаба у детей с аутовоспалительными заболеваниями и системным ювенильным артритом: описание серии случаев

Πηγή: Вопросы современной педиатрии.

Θεματικοί όροι: АУТОВОСПАЛИТЕЛЬНЫЕ ЗАБОЛЕВАНИЯ,СИСТЕМНЫЙ ЮВЕНИЛЬНЫЙ АРТРИТ,ЛЕЧЕНИЕ,ИНГИБИТОРЫ ИНТЕРЛЕЙКИНА 1,КАНАКИНУМАБ,AUTOINFLAMMATORY DISEASES,SYSTEMIC JUVENILE ARTHRITIS,TREATMENT,INTERLEUKIN-1 INHIBITORS,CANAKINUMAB, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article/n/primenenie-ingibitora-interleykina-1-kanakinumaba-u-detey-s-autovospalitelnymi-zabolevaniyami-i-sistemnym-yuvenilnym-artritom-opisanie
http://cyberleninka.ru/article_covers/16442108.png